<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001416.pub2" GROUP_ID="EPILEPSY" ID="557499080914015118" MERGED_FROM="" MODIFIED="2013-12-12 13:12:49 +0000" MODIFIED_BY="Rachael Kelly" REVIEW_NO="0030" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2013-12-12 13:12:49 +0000" MODIFIED_BY="Rachael Kelly">
<TITLE>Zonisamide add-on for drug-resistant partial epilepsy</TITLE>
<CONTACT MODIFIED="2013-12-12 13:12:49 +0000" MODIFIED_BY="Rachael Kelly"><PERSON ID="z1210041341321086591229062714631" ROLE="AUTHOR"><FIRST_NAME>Katie</FIRST_NAME><LAST_NAME>Carmichael</LAST_NAME><EMAIL_1>katie_carmichael@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT><ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION><ADDRESS_1>Clinical Sciences Centre for Research and Education, Lower Lane</ADDRESS_1><ADDRESS_2>Fazakerley</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L9 7LJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-12-12 13:12:49 +0000" MODIFIED_BY="Rachael Kelly"><PERSON ID="z1210041341321086591229062714631" ROLE="AUTHOR"><FIRST_NAME>Katie</FIRST_NAME><LAST_NAME>Carmichael</LAST_NAME><EMAIL_1>katie_carmichael@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT><ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION><ADDRESS_1>Clinical Sciences Centre for Research and Education, Lower Lane</ADDRESS_1><ADDRESS_2>Fazakerley</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L9 7LJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="12654466126280759364110830105954" ROLE="AUTHOR"><FIRST_NAME>Jennifer</FIRST_NAME><LAST_NAME>Pulman</LAST_NAME><EMAIL_1>jennifer.pulman@liv.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT><ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION><ADDRESS_1>Clinical Sciences Centre for Research and Education, Lower Lane</ADDRESS_1><ADDRESS_2>Fazakerley</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L9 7LJ</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="F02A205382E26AA2012E60F3302238F7" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Shaheen Emmanuel</FIRST_NAME><LAST_NAME>Lakhan</LAST_NAME><POSITION>Executive Director</POSITION><EMAIL_1>slakhan@gnif.org</EMAIL_1><URL>http://slakhan.gnif.org</URL><ADDRESS><ORGANISATION>Global Neuroscience Initiative Foundation</ORGANISATION><ADDRESS_1>9776 Peavine Dr</ADDRESS_1><CITY>Beverly Hills</CITY><ZIP>90210</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>818-574-3062</PHONE_1></ADDRESS></PERSON><PERSON ID="z1312121300366557189711158559443" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Prachi</FIRST_NAME><LAST_NAME>Parikh</LAST_NAME><EMAIL_1>prachi.parikh88@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Cleveland Clinic</ORGANISATION><ADDRESS_1>9500 Euclid Avenue, S100C</ADDRESS_1><CITY>Cleveland</CITY><ZIP>44195</ZIP><REGION>Ohio</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="555BA85182E26AA20187B7968786091D" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Anthony</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Marson</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>a.g.marson@liverpool.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT><ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION><ADDRESS_1>Clinical Sciences Centre for Research and Education, Lower Lane</ADDRESS_1><ADDRESS_2>Fazakerley</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L9 7LJ</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 529 5405</PHONE_1><PHONE_2>+44 151 529 5462</PHONE_2><FAX_1>+44 151 529 5465</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-12-12 11:54:32 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="12" MONTH="2" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="2" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="2" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2013-12-12 11:19:11 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-12-12 11:19:11 +0000" MODIFIED_BY="Katie Carmichael">
<DATE DAY="12" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>One new study has been included. Some adverse effects conclusions have changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-10-09 14:35:28 +0100" MODIFIED_BY="Katie Carmichael">
<DATE DAY="12" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>Searches updated 12 February 2013.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-10-16 17:13:15 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-03 09:56:20 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>We re-ran our searches on 15 July 2007; several new potentially relevant studies were identified. These have been added to the 'studies awaiting classification' section and will be assessed for inclusion in the near future.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-10-16 17:13:15 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="8" YEAR="2005"/>
<DESCRIPTION>
<P>We re-ran our searches on 1 August 2005, which identified one new study (<LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK>). This has been added to the review. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-12-12 11:10:15 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2013-11-04 09:55:18 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-11-04 09:55:18 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The review presents independent research commissioned by the National Institute for Health Research (NIHR). The views expressed in this publication are those of the authors(s) and not necessarily those of the NHS, the NIHR or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-12-12 13:10:50 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-12-12 11:21:08 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-03 09:46:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Comments (Statistician):&lt;/p&gt;&lt;p&gt;'Zonisamide significantly...' - Is this statement strictly true as it could be the combination of the two drugs rather than the zonisamide alone which is reducing seizure frequency?&lt;br&gt;The sentence could read better as &amp;quot;The review of trials found that seizure frequency was significantly reduced for people.... zonisamide is added to their usual treatment&amp;quot;&lt;/p&gt;&lt;p&gt;'placebo tablets..' - Placebo tablets in addition to their usual treatment (not implying a comparison to untreated people)&lt;/p&gt;&lt;p&gt;'adverse effects' - Such as?&lt;/p&gt;&lt;p&gt;Response from review authors:&lt;/p&gt;&lt;p&gt;Done. &lt;/p&gt;" NOTES_MODIFIED="2008-09-03 09:46:53 +0100" NOTES_MODIFIED_BY="[Empty name]">Zonisamide add-on for drug-resistant partial epilepsy</TITLE>
<SUMMARY_BODY MODIFIED="2013-11-04 10:11:42 +0000" MODIFIED_BY="[Empty name]">
<P>Zonisamide in combination with another antiepileptic drug can reduce seizures, but with some adverse effects.</P>
<P>Around 70% of epileptic patients can become seizure-free with antiepileptic drug treatment. The remaining 30% of people with epilepsy may be resistant to antiepileptic drugs and still experience seizures. Older drugs do not prevent seizures for everyone and they have adverse effects. New drugs have been developed to try to treat those people who are resistant to the old drugs and to try to limit the adverse effects. These newer drugs are taken as well as the patient's existing medication, as an 'add-on' treatment. Zonisamide is used as an add-on treatment.</P>
<P>A search of databases was carried out on 12/02/2013. Five trials were found which included 949 people with partial epilepsy. These trials were all randomised controlled trials which compared the antiepileptic drug Zonisamide to a placebo drug for a period of 12 weeks. Taking all the evidence of the trials into account, the review found that seizure frequency was significantly reduced for people with drug-resistant partial epilepsy if zonisamide is added to their usual treatment. Patients treated with 300 to 500 mg/day of zonisamide were twice as likely as people given placebo tablets in addition to their usual treatment to experience at least a 50% reduction in the frequency of their seizures. However, adding zonisamide to the usual treatment is associated with an increase in adverse effects such as problems with co-ordination (ataxia), drowsiness (somnolence), agitation and anorexia.</P>
<P>The trials were assessed with regards to bias and quality and overall, the quality of the evidence was rated as high quality. However more research is need which concentrates on examining the dose of zonisamide.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-12-12 11:21:58 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-06-18 22:29:53 +0100" MODIFIED_BY="Katie Carmichael">
<P>The majority of people with epilepsy have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarise the current evidence regarding zonisamide, when used as an add-on treatment for drug-resistant partial epilepsy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-10-07 14:38:38 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and tolerability of zonisamide when used as an add-on treatment for people with drug-resistant partial epilepsy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-10-29 14:55:32 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Epilepsy Group Specialized Register (12 February 2013), the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I>
<B> </B>2013, Issue 1) (January 2013), MEDLINE (Ovid, 1946 to 12 February 2013), SCOPUS (13 February 2013), <A HREF="http://clinicaltrials.gov/">ClinicalTrials.gov</A> (12 February 2013) and the <A HREF="http://apps.who.int/trialsearch/">WHO International Clinical Trials Registry Platform ICTRP</A> (13 February 2013). In addition, we contacted Eisai Limited (makers and licensees of zonisamide) and experts in the field to seek any ongoing/unpublished studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-10-29 14:55:34 +0000" MODIFIED_BY="Katie Carmichael">
<P>Randomised, placebo-controlled, add-on trials of zonisamide in people with drug-resistant partial epilepsy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-11-04 09:22:14 +0000" MODIFIED_BY="Katie Carmichael">
<P>Two review authors independently selected trials for inclusion and extracted data. Outcomes were: (1) 50% or greater reduction in total seizure frequency; (2) treatment withdrawal; (3) adverse effects. Primary analyses were intention-to-treat. We estimated summary risk ratios (RRs) for each outcome. All studies were assessed for risk of bias using the Cochrane risk of bias tool and the quality of evidence was assessed using the GRADE approach and presented in a summary of findings table. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-12-12 11:21:58 +0000" MODIFIED_BY="Katie Carmichael">
<P>Five trials (949 participants) were included. The overall RR with 95% confidence interval (CI) for 50% reduction in seizure frequency compared to placebo for 300 to 500 mg/day of zonisamide was 2.00 (95% CI 1.58 to 2.54). The RR for 50% reduction in seizure frequency compared to placebo for any dose of zonisamide (100 to 500 mg per day) was 1.92 (95% CI 1.52 to 2.42). The number needed to treat (NNT) was 6 for this outcome. Two trials provide evidence of a dose response relationship for this outcome. The RR for treatment withdrawal for 300 to 500 mg/day of zonisamide compared to placebo was 1.64 (95% CI 1.20 to 2.25) and for 100 to 500 mg per day was 1.47 (95% CI 1.07 to 2.01). NNT for this outcome was 21. The CIs of the following adverse effects indicate that they are significantly associated with zonisamide: ataxia 3.77 (99% CI 1.28 to 11.11); somnolence 1.83 (99% CI 1.08 to 3.11); agitation 2.35 (99% CI 1.05 to 5.27) and anorexia 2.71 (99% CI 1.29 to 5.69). Across the 5 studies, risk of bias domains were rated as low is bias or unclear. None of the evidence for outcomes was downgraded for quality.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-10-29 14:55:45 +0000" MODIFIED_BY="Katie Carmichael">
<P>Zonisamide has efficacy as an add-on treatment in people with drug-resistant partial epilepsy. In this review minimum effective and maximum tolerated doses cannot be identified. The trials reviewed were of a maximum stable-dose phase of 18 weeks in duration and results cannot be used to confirm longer periods of effectiveness in seizure control. The results cannot be extrapolated to monotherapy or to people with other seizure types or epilepsy syndromes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-12-12 11:53:19 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-10-29 14:56:07 +0000" MODIFIED_BY="Katie Carmichael">
<P>Standard antiepileptic drugs (AEDs) (e.g. carbamazepine, phenytoin, valproate) do not control all patients' seizures and cause a number of side effects. Over the past 15 to 20 years, therefore, there has been renewed interest in the development of new AEDs. Several new AEDs are now licensed for use as an 'add-on' treatment in a variety of countries: felbamate; gabapentin; lamotrigine; levetiracetam; oxcarbazepine; pregabalin; tiagabine; topiramate; vigabatrin and zonisamide.</P>
<P>In this review we investigate the efficacy and tolerability of add-on zonisamide in people with drug-resistant partial epilepsy. For the purpose of this review, people with drug-resistant partial epilepsy have been defined as having partial onset seizures (simple partial and/or complex partial and/or secondary generalised tonic-clonic seizures) that have failed to respond to monotherapy with a standard AED. This review is part of a series of reviews investigating the new AEDs.</P>
<CONDITION MODIFIED="2013-10-29 14:55:58 +0000" MODIFIED_BY="Katie Carmichael">
<P>Epilepsy is a common neurological condition, with an estimated incidence of 50 per 100,000 and prevalence of 5 to 10 per 1000 in the developed world (<LINK REF="REF-Sander-1996" TYPE="REFERENCE">Sander 1996</LINK>). Between two and three per cent of the population will be given a diagnosis of epilepsy at some time in their lives, the majority of whom will go into remission. However, up to 30% will fail to respond to monotherapy (<LINK REF="REF-Cockerell-1995" TYPE="REFERENCE">Cockerell 1995</LINK>; <LINK REF="REF-Hauser-1993" TYPE="REFERENCE">Hauser 1993</LINK>), often requiring treatment with combinations of AEDs. These individuals will often experience significant adverse psychological and quality of life outcomes, due to continued and unpredictable seizures, side effects of drugs, and reduced education and employment prospects.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-10-29 14:56:04 +0000" MODIFIED_BY="Katie Carmichael">
<P>In the majority of cases, epilepsy is treated using AEDs. These AEDs have varying mechanisms of action and certain AEDs are more effective at treating specific seizure types. For example, carbamazepine is more effective for focal seizures (<LINK REF="REF-Marson-2000" TYPE="REFERENCE">Marson 2000</LINK>) and valproate is more effective for generalised onset seizures (<LINK REF="REF-Marson-2007" TYPE="REFERENCE">Marson 2007</LINK>). Conventional first-line drugs include carbamazepine, lamotrigine and sodium valproate, which have a broad therapeutic effect but are associated with a number of adverse effects. In cases where monotherapy fails to induce seizure remission, AED 'add-on therapy' may be used in an attempt to improve seizure control. Zonisamide is one such add-on therapy. Zonisamide is a synthetic 1,2-benzisoxazole-3-methanesulfonamide with anticonvulsant properties (<LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK>). Zonisamide has a long half-life (63 to 69 hours) (<LINK REF="REF-Baulac-2007" TYPE="REFERENCE">Baulac 2007</LINK>) and the typical maintenance dose in adults over the age of 18 is 300 to 500 mg/day, possibly split in to two doses per day (<LINK REF="REF-British-National-Formulary" TYPE="REFERENCE">British National Formulary</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-10-29 14:56:07 +0000" MODIFIED_BY="Katie Carmichael">
<P>Proposed neuropharmacological mechanisms of action for zonisamide include blockade of voltage-sensitive sodium channels, blockade of voltage-dependent T-type calcium channels, blockade of potassium-evoked glutamate response, reduced glutamate-mediated synaptic excitation (<LINK REF="REF-Leppik-2004" TYPE="REFERENCE">Leppik 2004</LINK>) and increased synaptic concentration of gamma-aminobutyric acid (GABA) (<LINK REF="REF-Ueda-2003" TYPE="REFERENCE">Ueda 2003</LINK>). It has been proposed that zonisamide might help patients who are resistant to other AEDs because it blocks both voltage-sensitive sodium and T-type calcium channels (<LINK REF="REF-Leppik-2004" TYPE="REFERENCE">Leppik 2004</LINK>). Although zonisamide does not induce liver enzymes, it is metabolised by cytochrome P450. Therefore concomitant AEDs which are liver enzyme-inducing will enhance zonisamide metabolism and so the zonisamide dosage strategy may need to be adjusted to compensate for the effect of other AEDs (<LINK REF="REF-Leppik-2004" TYPE="REFERENCE">Leppik 2004</LINK>). By scavenging hydroxyl and nitric oxide free radicals, zonisamide may also be neuroprotective (<LINK REF="REF-Mori-1998" TYPE="REFERENCE">Mori 1998</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-10-08 14:42:53 +0100" MODIFIED_BY="Katie Carmichael">
<P>While the majority of people with epilepsy do respond to AEDs, a treatment solution needs to be found for the 30% who do not. This review update aims to inform clinical practitioners as to the efficacy and tolerability of zonisamide when used as add-on therapy to treat patients with drug-refractory partial epilepsy.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the efficacy and tolerability of zonisamide when used as an add-on treatment for people with drug-resistant partial epilepsy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-12-12 11:50:59 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-12-12 11:50:59 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-10-29 14:56:18 +0000" MODIFIED_BY="Katie Carmichael">
<OL>
<LI>Randomised controlled trials, in which an adequate method of concealment of randomisation was used (e.g. allocation of sequentially numbered, sealed packages of medication, sealed opaque envelopes, telephone randomisation).</LI>
<LI>Double-blind trials, in which both participant and clinician treating or assessing outcome are blinded to treatment allocated.</LI>
<LI>Placebo-controlled.</LI>
<LI>Parallel-group or cross-over studies.</LI>
<LI>Minimum treatment period of eight weeks. This period was selected as it represents the minimum time over which changes in seizure frequency can be determined, given the propensity of seizures to occur in clusters.</LI>
<LI>Studies using a response conditional design would have been excluded, however none were found. In this type of study, participants are given active treatment during a pre-randomisation baseline period, and only those having a pre-defined response to treatment are allocated to treatment groups. We decided to exclude this type of trial as they are really evaluating the effect of drug withdrawal in a highly selected population of individuals. In addition, there is no drug-free baseline from which a reduction in seizure frequency can be calculated.</LI>
<LI>Head-to-head drug trials where zonisamide is compared directly to another add-on AED.</LI>
</OL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-10-29 14:56:19 +0000" MODIFIED_BY="[Empty name]">
<P>Participants of any age with drug-resistant partial epilepsy (i.e. experiencing simple partial, complex partial or secondary generalised tonic-clonic seizures).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-10-29 14:56:21 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>The active treatment group received treatment with zonisamide in addition to conventional AED treatment.</LI>
<LI>The control group received matched placebo in addition to conventional AED treatment.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-12-12 11:50:59 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-10-17 09:21:34 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">(1) Efficacy</HEADING>
<P>Proportion of participants with a 50% or greater reduction in seizure frequency in the treatment period compared to the pre-randomisation baseline period. We chose this outcome as it is commonly reported in this type of study, and can be calculated for studies that do not report this outcome provided that baseline seizure data were recorded.</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-12-12 11:50:59 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">(2) Tolerability</HEADING>
<P>The proportion of participants having treatment withdrawn during the course of the treatment period was used as a measure of global tolerability. Treatment is likely to be withdrawn due to adverse effects, lack of efficacy or a combination of both, and this is an outcome to which participants can make a direct contribution. In trials of short duration it is likely that adverse effects will be the most common reason for withdrawal.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Adverse effects</HEADING>
<UL>
<LI>The proportion of participants experiencing any of the following five adverse effects, that are found through research to be common and important adverse effects of AEDs:</LI>
<UL>
<LI>ataxia;</LI>
<LI>dizziness;</LI>
<LI>fatigue;</LI>
<LI>nausea;</LI>
<LI>somnolence.</LI>
</UL>
<LI>The proportion of participants experiencing the five most common adverse effects if different from (a) above (also <I>see </I>
<LINK TAG="METHODS" TYPE="SECTION">Methods</LINK>).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-12-12 11:43:24 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-12-12 11:43:24 +0000" MODIFIED_BY="Katie Carmichael">
<P>We searched the following databases. There were no language restrictions.</P>
<OL>
<LI>Cochrane Epilepsy Group Specialized Register (12 February 2013), using the search strategy outlined in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>
</LI>
<LI>The Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I> Issue 1, January 2013), using the search strategy outlined in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</LI>
<LI>MEDLINE (Ovid, 1946 to 12 February 2013) using the search strategy outlined in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</LI>
<LI>SCOPUS (13 February 2013) using the search strategy outlined in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>
</LI>
<LI>
<A HREF="http://clinicaltrials.gov/">ClinicalTrials.gov</A> (12 February 2013) - searched for "zonisamide and epilepsy".</LI>
<LI>
<A HREF="http://apps.who.int/trialsearch/">WHO International Clinical Trials Registry Platform ICTRP</A> (13 February 2013) - searched for "zonisamide and epilepsy".</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-10-29 14:56:40 +0000" MODIFIED_BY="Katie Carmichael">
<P>In addition, we contacted Eisai Limited (makers and licensees of zonisamide) and experts in the field to seek any ongoing or unpublished studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-10-29 14:57:53 +0000" MODIFIED_BY="Katie Carmichael">
<STUDY_SELECTION MODIFIED="2013-10-29 14:56:41 +0000" MODIFIED_BY="Katie Carmichael">
<P>Two review authors (Katie Carmichael and Jennifer Pulman) independently assessed trials for inclusion. Any disagreement was resolved by mutual discussion.</P>
<P>The same two review authors, together with Shaheen Lakhan, extracted the following information from included trials; we resolved disagreements by majority decision.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-10-29 14:56:55 +0000" MODIFIED_BY="Katie Carmichael">
<P>We extracted the following information for each trial using a data extraction sheet:</P>
<SUBSECTION>
<HEADING LEVEL="4">Methodological/trial design</HEADING>
<OL>
<LI>Method of randomisation and allocation concealment.</LI>
<LI>Method of blinding.</LI>
<LI>Whether any participants had been excluded from reported analyses.</LI>
<LI>Duration of baseline period.</LI>
<LI>Duration of treatment period.</LI>
<LI>Dose(s) of zonisamide tested.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participant/demographic information</HEADING>
<OL>
<LI>Total number of participants allocated to each treatment group.</LI>
<LI>Age/sex.</LI>
<LI>Number with partial/generalised epilepsy.</LI>
<LI>Seizure types.</LI>
<LI>Seizure frequency during the baseline period.</LI>
<LI>Number of background drugs.</LI>
</OL>
<P>Four of the five studies found so far have been sponsored by Eisai (no source of funding was used to assist in the conduct of the <LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK> trial). They have supplied copies of internal trial reports which will be used to confirm the following information.</P>
<OL>
<LI>The method of randomisation.</LI>
<LI>The total number randomised to each group.</LI>
<LI>The number of people in each group achieving a 50% or greater reduction in seizure frequency per treatment group.</LI>
<LI>The number of people having treatment withdrawn post-randomisation per treatment group.</LI>
<LI>For those excluded:</LI>
<OL>
<LI>the reason for exclusion;</LI>
<LI>whether any of those excluded completed the treatment phase;</LI>
<LI>whether any of those excluded had a 50% or greater reduction in seizure frequency during the treatment phase.</LI>
</OL>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>We recorded the number of participants experiencing each outcome (see<I> </I>
<LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>) per randomised group.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-10-29 14:57:00 +0000" MODIFIED_BY="Katie Carmichael">
<P>Two review authors (Katie Carmichael and Shaheen Lakhan) independently assessed risk of bias for each of the five included trials using the Cochrane 'Risk of bias' tool as found in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Any disagreement in the assessment of the level of bias was resolved by a third party. We extracted data from the five included studies relating to sequence generation, concealment of allocation, methods of blinding, incomplete outcome data, selective reporting and other types of bias. We made a judgement of the level of bias involved for each of these categories for all included studies.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-10-29 14:57:03 +0000" MODIFIED_BY="Katie Carmichael">
<P>We presented the outcomes 50% of greater reduction in seizure frequency, treatment withdrawal and adverse effects as risk ratios (RR).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-10-29 14:57:03 +0000" MODIFIED_BY="Katie Carmichael">
<P>There were no special issues to consider with the design of the included studies. All included studies utilised a parallel design, four with a stable-dose phase of 12 weeks and one with a stable-dose phase of 18 weeks.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-10-29 14:57:07 +0000" MODIFIED_BY="Katie Carmichael">
<P>We conducted intention-to-treat, best-case and worst-case analyses to account for any missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-10-29 14:57:19 +0000" MODIFIED_BY="Katie Carmichael">
<P>We assessed clinical heterogeneity by evaluating similarities and differences in the methodologies and outcomes measured in the included studies and by visually inspecting forest plots. We assessed statistical heterogeneity using the Chi<SUP>2 </SUP>test and I<SUP>2 </SUP>statistic according to section 9.5.2 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>): 0% to 40% might not be important, 30% to 60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity, and 75% to 100% indicating considerable heterogeneity. Our intention was to utilise a fixed-effect model if no statistically significant heterogeneity was found between the included studies. If statistical heterogeneity had been present we would have employed a random-effects model.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-10-29 14:57:26 +0000" MODIFIED_BY="Katie Carmichael">
<P>We contacted authors of all included studies and requested trial protocols in order to identify any discrepancies between protocol and trial methodology.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-10-29 14:57:47 +0000" MODIFIED_BY="Katie Carmichael">
<P>We utilised a fixed-effect meta-analysis to synthesise the collected data. Planned comparisons included:</P>
<OL>
<LI>50% or greater reduction in seizure frequency in the intervention group versus the control group;</LI>
<LI>treatment withdrawal rates in the intervention group versus the control group;</LI>
<LI>adverse effects in the intervention group versus the control group.</LI>
</OL>
<P>The preferred estimator was the Mantel-Haenszel risk ratio (RR). We used 95% confidence intervals (CIs) for 50% or greater reduction in seizure frequency and treatment withdrawal outcomes. We used a 99% CI for the adverse effects outcome. All analyses included all participants who had been randomised to the group to which they were allocated. For the 50% or greater reduction in seizure frequency outcome, we conducted three analyses:</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Primary (intention-to-treat) analysis</HEADING>
<P>Participants not completing follow-up or with inadequate seizure data are assumed to be non-responders.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Worst-case analysis</HEADING>
<P>Participants not completing follow-up or with inadequate seizure data are assumed to be non-responders in the zonisamide group and responders in the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Best-case analysis</HEADING>
<P>Participants not completing follow-up or with inadequate seizure data are assumed to be responders in the zonisamide group and non-responders in the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dose regression analysis</HEADING>
<P>We planned to examine dose response relationships using logistic regression, in the framework of generalised linear models (<LINK REF="REF-McCullagh-1989" TYPE="REFERENCE">McCullagh 1989</LINK>). The structure of the data within the trials did not allow this approach (see <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK>).</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-10-29 14:57:52 +0000" MODIFIED_BY="Katie Carmichael">
<P>We conducted subgroup analysis for adverse effect data and produced risk ratios for each different adverse effect. We also conducted subgroup analysis for mg/day dose of zonisamide.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-10-29 14:57:53 +0000" MODIFIED_BY="Katie Carmichael">
<P>If trial methodologies were found to be sufficiently distinct, we conducted sensitivity analysis in order to identify which factor(s) were influential in the degree of heterogeneity.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-12-12 09:33:14 +0000" MODIFIED_BY="Katie Carmichael">
<STUDY_DESCRIPTION MODIFIED="2013-10-29 14:58:12 +0000" MODIFIED_BY="Katie Carmichael">
<P>Once any duplicates were removed, the literature search resulted in 292 records being identified from the Cochrane Epilepsy Group Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, SCOPUS, <A HREF="http://clinicaltrials.gov">clinicaltrials.gov</A> and <A HREF="http://apps.who.int/trialsearch/">WHO International Clinical Trials Registry Platform ICTRP</A>. We removed 86 duplicated records and screened the remaining 206 records for suitability. We excluded 199 records after initial screening and assessed the full text of the remaining seven articles in order to ascertain eligibility for inclusion based on the extent to which the records met the inclusion criteria. Four records were identified as having met the inclusion criteria for the previous version of this review. One new record met the inclusion criteria and so a total of five records were included in this review update. One of the remaining two records was deemed ineligible and was excluded from this review (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The full report for the other study was unobtainable and was placed in awaiting classification.</P>
<P>The five included studies (949 participants) were parallel-group (although <LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK> added a cross-over phase for all participants in the final five weeks) with a stable-dose phase of 12 or 18 weeks. Two studies (<LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK>; <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>) allowed some dose titration according to seizure response and tolerability. In both studies the median daily dose for participants completing the study was 400 mg. A third study (<LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK>) titrated to 400 mg/day, but participants randomised to zonisamide followed different rates of titration during the first five weeks of the study, which allowed some comparison of placebo, 100 mg/day and 200 mg/day during this period of the study. In the fourth study (<LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK>) participants were randomised to placebo, 100 mg, 300 mg or 500 mg of zonisamide in a 2:1:1:2 ratio, allowing further investigation of dose response relationships. In the newly included study (<LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK>) two different titration strategies were utilised; in the first, a 100 mg/day zonisamide dose was given for the first two weeks after baseline, 200 mg/day for the third week and 300 mg/day from week four onwards. The initial dose in the second strategy was 100 mg/day of zonisamide increasing weekly by increments of 100 mg/day until a target of 400 mg/day was reached in week four and continued onwards for the duration of the trial. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for full details of the included studies.</P>
<P>One add-on study compared zonisamide with valproate rather than placebo in a head-to-head trial (<LINK REF="STD-Anderson-1988" TYPE="STUDY">Anderson 1988</LINK>) which did meet the inclusion criteria. However, only a single-page summary was available, which gave too little information on methods or outcome data. We are therefore currently unable to include information from this trial in the review (see <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>). <LINK REF="STD-Shimizu-1988" TYPE="STUDY">Shimizu 1988</LINK> was excluded as no control group was used (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-10-29 14:58:50 +0000" MODIFIED_BY="Katie Carmichael">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for a summary of the risk of bias in the included studies.</P>
<ALLOCATION MODIFIED="2013-10-29 14:58:22 +0000" MODIFIED_BY="Katie Carmichael">
<P>In three studies allocation was concealed by dispensing sequentially numbered packages to each participant (<LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK>; <LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK>; <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>), whilst <LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK> used a telephone randomisation service. In two studies (<LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK>; <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>) patients were assigned to groups in blocks of six and four respectively. Randomisation codes were generated centrally (<LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK>) or by the study sponsor (<LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK>). <LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK> used a process of restricted randomisation as zonisamide and placebo were assigned in a ratio of 1:1.</P>
<P>Patient codes were hidden by use of numbered containers (<LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK>; <LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK>) or sealed envelopes containing an individual patient code (<LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK>). However, the appearance of the items used to conceal codes was not explicitly described so it cannot be certain how effective these concealment methods were.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-10-29 14:58:30 +0000" MODIFIED_BY="Katie Carmichael">
<P>We deemed all five of the included studies to be at low risk of performance bias (participants) as placebo and zonisamide tablets were identical in appearance (<LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK>; <LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK>; <LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK>; <LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK>; <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>). Blinding of outcome assessors was not detailed in any of the included studies and we therefore classified this as being at an unclear risk of bias. However, patients self reported seizure frequency and duration and therefore we thought that a lack of detail on the outcome assessors would have a minimal impact overall. One trial report (<LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>) did not provide any detail with regard to blinding of study personnel or outcome assessors and as such was classified as being at unclear risk of bias overall.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-10-29 14:58:36 +0000" MODIFIED_BY="Katie Carmichael">
<P>We classified the trials <LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK> and <LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK> as being at a low risk of attrition bias overall as few participants left the study for any reason before completion and these participants were reasonably evenly spread across the different intervention groups. We assessed <LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK> to be at an unclear risk of attrition bias due to unclear reporting of missing data and study attrition rates. <LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK> did not clearly report all data in relation to study attrition and missing data. The attrition rate was not clearly reported in the trial by <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK> and as such we classified it as being at an unclear risk of attrition bias.</P>
<P>All of the trials conducted a modified version of an intention-to-treat (ITT) analysis, while one trial also conducted a second, unmodified ITT analysis (<LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK>). Four trials failed to include all randomised participants in their ITT analysis (<LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK>; <LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK>; <LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK>) and instead omitted participants who had not completed the trial for any reason. In these four trials participants were included in the ITT analysis if they had taken at least one dose of the intervention to which they had been allocated. The fifth trial (<LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>) also conducted a modified ITT analysis, but instead included participants who had received at least seven days of treatment.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-10-29 14:58:43 +0000" MODIFIED_BY="Katie Carmichael">
<P>We contacted all study authors but no included trial protocols were made available. All primary and secondary outcomes outlined in the methods section of each trial were analysed and reported in the results section of each study and we therefore classified them as being at a low risk of reporting bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-10-29 14:58:50 +0000" MODIFIED_BY="Katie Carmichael">
<P>One potential source of bias would be the unequal duration of stable-dose phase depending on which dosage group a participant had been allocated to. Specifically, in one study (<LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK>) participants allocated to the 100 mg/day zonisamide dose were on a stable dose for 23 weeks in total as their titration phase was relatively brief in comparison to those participants in the 300 mg/day and 500 mg/day groups who had a stable-dose phase of 20 and 18 weeks respectively. Both sponsors of one trial were manufacturers of zonisamide (<LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK>). Two studies extended the baseline period by four weeks if participants did not experience 15 or more seizures in the first four weeks of baseline, or 30 or more seizures in the first eight weeks of baseline (<LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK>; <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>). This manipulation may have artificially inflated the effect of zonisamide on seizure frequency making any reduction in seizures attributed to zonisamide of a greater magnitude by comparison. Conversely, this extension of the baseline period may have increased the likelihood of regression to the mean.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-12-12 09:33:14 +0000" MODIFIED_BY="Katie Carmichael">
<SUBSECTION>
<HEADING LEVEL="3">Efficacy: 50% or greater reduction in seizure frequency</HEADING>
<P>The study of <LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK> allocated patients to placebo or to one of two zonisamide groups. Both groups were titrated up to 400 mg per day, but according to two different regimes. One group took 100 mg in weeks one to five, 200 mg in week six, 300 mg in week seven and 400 mg in weeks eight to 12. The second group took 100 mg in week one, 200 mg in weeks two to six, 300 mg in week seven and 400 mg in weeks eight to 12. Data from weeks two to five provide estimates of the response rates for 100 mg and 200 mg of zonisamide, whilst data from weeks eight to 12 provide an estimate of the response rate for 400 mg zonisamide.</P>
<P>For <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK> and <LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK>, patients allocated zonisamide had the dose titrated up to a median of 400 mg per day over weeks one to four, and then entered a stable-dose period over weeks five to 12. Similarly in <LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK>, doses were titrated up over six weeks and stable for a further 18 weeks. <LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK> utilised a four-week titration period where patients were taken up to the target dose of either 300 or 400 mg/day of zonisamide (dependent on which sponsor group they were in) before entering a 12-week stable-dose phase.</P>
<P>Analysis of participants who experienced a 50% or greater reduction in their seizure frequency (responders) included data from the whole treatment period (titration plus stable-dose phase). Given that the median dose was 400 mg in <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK> and <LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK>, the target dose in <LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK> was 400 mg, and the target dose in <LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK> was either 300 mg/day or 400 mg/day, analyses are presented which include data from all groups in <LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK> (100 mg, 300 mg, 500 mg), as well as analyses excluding the 100 mg group in that study.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Whole treatment period analysis</HEADING>
<P>For the analysis using any dose of zonisamide there was no statistical heterogeneity among trials (I<SUP>2 </SUP>= 0%) and the overall risk ratio (RR) was 1.92 (95% confidence interval (CI) 1.52 to 2.42) indicating a significant effect of zonisamide. Results excluding the 100 mg group from <LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK> are similar: RR 2.00 (95% CI 1.58 to 2.54). NNT calculations show that approximately 6 patients need to be treated with zonisamide for every additional patient with a 50% response. </P>
<P>Both analyses indicate a significant treatment effect (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Best and worst-case scenarios</HEADING>
<P>We calculated these using data for the whole treatment period and for all doses of zonisamide. For the best-case scenario the overall RR was 2.23 (95% CI 1.78 to 2.79) and for the worst-case was 1.42 (95% CI 1.16 to 1.75) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). These results are consistent with a significant effect of zonisamide.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Dose response regression</HEADING>
<P>
<LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK> and <LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK> provide data for differing doses of zonisamide. Due to differences in the design of the trials we thought it inappropriate to combine these data in a meta-analysis. For <LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK> estimates are as follows: 100 mg (RR 1.70; 95% CI 0.98 to 2.97); 300 mg (RR 1.94; 95% CI 1.14 to 3.31) and 500 mg (RR 2.66; 95% CI 1.73 to 4.11). Estimates indicate increasing efficacy with increasing dose (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). For <LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK> there is no clear relationship between dose and response: 100 mg (RR 1.93; 95% CI 0.96 to 3.91), 200 mg (RR 2.26; 95% CI 1.15 to 4.48) and 400 mg (RR 1.74; 95% CI 1.11 to 2.75) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Tolerability: treatment withdrawal for any reason</HEADING>
<P>We undertook analyses including and excluding the 100 mg group from <LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK>. For both analyses there was no statistical heterogeneity (I<SUP>2 </SUP>= 0%). For any dose of zonisamide the RR is 1.47 (95% CI 1.07 to 2.01)and excluding the 100 mg group from <LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK> the RR is 1.64 (95% CI 1.20 to 2.25) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>Patients are therefore significantly more likely to withdraw from zonisamide than from placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>In addition to the reports of ataxia, dizziness, fatigue, nausea and somnolence, agitation and anorexia were among the five most common adverse effects and have therefore been included in this analysis. The confidence intervals for the following adverse effects do not include unity: ataxia (RR 3.77; 99% CI 1.28 to 11.11); somnolence (RR 1.83; 99% CI 1.08 to 3.11); agitation (RR 2.35; 99% CI 1.05 to 5.27) and anorexia (RR 2.71; 99% CI 1.29 to 5.69), indicating a statistically significant association between zonisamide and these symptoms. All symptoms were more frequent with zonisamide than placebo.</P>
<P>The CIs of the following adverse effects indicate that they are not significantly associated with zonisamide: dizziness (RR 1.46; 99% CI 0.88 to 2.44, P = 0.05); nausea (RR 1.21; 99% CI 0.61 to 2.40, P = 0.46) and fatigue (RR 1.41; 99% CI 0.76 to 2.62, P = 0.16) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
<P>NNT calculations show that approximately 21 patients need to be treated with zonisamide for every patient withdrawing compared to placebo. </P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-11-04 09:41:00 +0000" MODIFIED_BY="Katie Carmichael">
<SUMMARY_OF_RESULTS MODIFIED="2013-11-04 09:41:00 +0000" MODIFIED_BY="Katie Carmichael">
<P>Four trials included in this review were sponsored by industry (Dainippon or Elan Pharma). No sources of funding were used to assist in the conduct or preparation of <LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK>, but the drug was provided for the trial by two different manufacturers of zonisamide (Eisai Co. Ltd and Shenzhen Zifu Co. Ltd).</P>
<P>All included studies were double-blind and four were at low risk of bias due to having used adequate methods of allocation concealment (<LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK>; <LINK REF="STD-Faught-2001" TYPE="STUDY">Faught 2001</LINK>; <LINK REF="STD-Lu-2011" TYPE="STUDY">Lu 2011</LINK>; <LINK REF="STD-Sackellares-2004" TYPE="STUDY">Sackellares 2004</LINK>), while this risk was unclear in one study (<LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK>). The detailed internal company report of <LINK REF="STD-Schmidt-1993" TYPE="STUDY">Schmidt 1993</LINK> indicates that 144 participants were randomised into this study, although the published paper indicates that 139 participants were randomised. The numbers of responders differs slightly because, for this review, we have considered only the eight weeks immediately before randomisation to constitute the baseline, rather than a varied period of between eight to 12 weeks. The incidence of adverse events of different types differs as we have used figures derived from a later application of an updated lexicon and correction of previous duplicate reporting.</P>
<P>The intention-to-treat analysis shows that zonisamide reduces seizure frequency in people with drug-resistant partial epilepsy. There is a large discrepancy between estimates derived from worst and best-case scenarios indicating that the estimates from the intention-to-treat analysis should be regarded with some caution, although this analysis gives the most pragmatic assessment of treatment effect as all participants withdrawing prematurely are regarded as non-responders. The data from <LINK REF="STD-Brodie-2005" TYPE="STUDY">Brodie 2005</LINK> provide some evidence of a dose response relationship, although minimal effective or maximal tolerated doses have not yet been defined. Treatment in the randomised controlled trials reviewed ranged from 12 to 18 weeks, so that no conclusions can be drawn about longer-term efficacy.</P>
<P>Results for the outcome 'withdrawal of allocated treatment' indicate that zonisamide is more likely to be associated with withdrawal than placebo, an effect that is likely to be related to a higher incidence of adverse effects with active drug treatment. Somnolence, anorexia, agitation and ataxia were the most common adverse effects that were statistically more likely to occur on zonisamide than placebo. These clinical trials do not provide meaningful information about important safety issues such as acute idiosyncratic drug reactions, chronic toxicity or teratogenicity.</P>
<P>While this review offers proof of the efficacy of zonisamide for partial epilepsy as adjunctive treatment, it does not allow comparison with other AEDs. Prospective, actively controlled studies will be necessary to address this question. Similarly this review provides no information to support the use of zonisamide as either monotherapy or in people with other epilepsy syndromes. None of the studies included in this review recruited significant numbers of children and some caution should be exercised in extrapolating the results from adult studies to children with partial epilepsy.</P>
</SUMMARY_OF_RESULTS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-10-29 14:59:59 +0000" MODIFIED_BY="Katie Carmichael">
<P>We used the GRADE approach to assess the quality of evidence of the included studies and this information is displayed in a 'Summary of findings' table (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). No studies were downgraded from high quality.</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-10-29 15:00:06 +0000" MODIFIED_BY="Katie Carmichael">
<IMPLICATIONS_PRACTICE MODIFIED="2013-10-29 15:00:05 +0000" MODIFIED_BY="Katie Carmichael">
<P>People with drug-resistant partial epilepsy were twice as likely to experience at least a 50% reduction in the frequency of their seizures when they took 300 to 500 mg/day of zonisamide compared to a placebo group, when treated over a stable-dose period of up to 18 weeks. For the patients entered into the trials, approximately six patients needed to be treated with zonisamide for every additional patient with a 50% response compared to placebo, i.e. for the population recruited into the trials, the number needed to treat was six.</P>
<P>Ataxia, somnolence, agitation and anorexia were the most common adverse effects attributable to zonisamide. Patients treated with zonisamide were more likely to have treatment withdrawn. For the patients entered into the trials, approximately 21 needed to be treated with zonisamide for every additional patient withdrawing compared to placebo, i.e. for the population recruited into the trials, the number needed to treat for an additional harmful outcome was 21.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-10-29 15:00:06 +0000" MODIFIED_BY="[Empty name]">
<P>There is a need for studies that more adequately explore the dose response relationship for zonisamide in partial and other epilepsy syndromes. Zonisamide should be compared to other new and standard AEDs as both add-on and monotherapy. With regards to the design of trials, thought should be given to the dynamics of the baseline period in order to prevent over-estimating the efficacy of the drug.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-10-08 09:24:18 +0100" MODIFIED_BY="Katie Carmichael">
<P>We thank Dainippon, Elan Pharma and Eisai for sharing unpublished and additional data for this review. We acknowledge David Chadwick for conducting the previous review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-11-04 09:45:53 +0000" MODIFIED_BY="Katie Carmichael">
<P>Professor Marson has received hospitality from Eisai. No other declarations of interest. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-12-12 13:10:50 +0000" MODIFIED_BY="Katie Carmichael">
<P>Katie Carmichael and Jen Pulman independently assessed trials for inclusion and Katie Carmichael, Shaheen Lakhan and Prachi Parikh independently extracted data. Anthony Marson supervised the entire review process and provided advice and guidance.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-02-04 09:35:29 +0000" MODIFIED_BY="Katie Carmichael">
<P>We considered head-to-head drug trials for inclusion in this review update. However, no such trials met the inclusion criteria. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-12-12 11:20:31 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-12-12 11:19:46 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-12-12 11:19:19 +0000" MODIFIED_BY="Katie Carmichael">
<STUDY DATA_SOURCE="PUB" ID="STD-Brodie-2005" MODIFIED="2013-06-18 22:49:14 +0100" MODIFIED_BY="Katie Carmichael" NAME="Brodie 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-06-18 22:48:07 +0100" MODIFIED_BY="Katie Carmichael" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitensky V</AU>
<TI>Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study</TI>
<SO>Epilepsia</SO>
<YR>2004</YR>
<VL>45</VL>
<NO>Suppl 3</NO>
<PG>155</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005; 46(1):31-41.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C</AU>
<TI>Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures</TI>
<SO>Epilepsia</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>1</NO>
<PG>31-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-18 22:48:22 +0100" MODIFIED_BY="Katie Carmichael" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodie MJ, Vespignani H, Solyom A, Bitensky V</AU>
<TI>Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Epilepsia</SO>
<YR>2004</YR>
<VL>45</VL>
<NO>Suppl 7</NO>
<PG>131</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-18 22:49:14 +0100" MODIFIED_BY="Katie Carmichael" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodie MJ, Vespignani H</AU>
<TI>Efficacy of zonisamide against refractory partial seizures in an evaluable patient population</TI>
<SO>Epilepsia</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>Suppl 6</NO>
<PG>117-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Faught-2001" NAME="Faught 2001" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Faught E, Ayala R, Montouris G, Leppik IE</AU>
<TI>Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>10</NO>
<PG>1774-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2011" MODIFIED="2013-10-29 15:02:46 +0000" MODIFIED_BY="Katie Carmichael" NAME="Lu 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-10-29 15:02:46 +0000" MODIFIED_BY="Katie Carmichael" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lu Y, Xiao Z, Yu W, Xiao F, Xiao Z, Hu Y et al</AU>
<TI>Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>4</NO>
<PG>221-9</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:50:47 +0000" MODIFIED_BY="Katie Carmichael"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sackellares-2004" MODIFIED="2013-12-12 11:19:19 +0000" MODIFIED_BY="Katie Carmichael" NAME="Sackellares 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-12 11:19:19 +0000" MODIFIED_BY="Katie Carmichael" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sackellares JC, Ramsay RE, Wilder BJ, Browne III TR, Shellenberger MK</AU>
<TI>Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures</TI>
<SO>Epilepsia</SO>
<YR>2004</YR>
<VL>45</VL>
<NO>6</NO>
<PG>610-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Wilder BJ, Ramsay RE, Guterman A. A double blind multicenter placebo controlled study of the effecacy of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dainippon Pharmaceutical Co., 1986.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Wilder BJ, Ramsay RE, Guterman A</AU>
<TI>A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients</TI>
<SO>Internal report of the Dainippon Pharmaceutical Company</SO>
<YR>1986</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schmidt-1993" MODIFIED="2013-02-01 10:19:50 +0000" MODIFIED_BY="Katie Carmichael" NAME="Schmidt 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-02-01 10:19:50 +0000" MODIFIED_BY="Katie Carmichael" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt D, Jacob R, Loiseau P, Deisenhammer E, Klinger D, Despland A et al</AU>
<TI>Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial</TI>
<SO>Epilepsy Research</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>1</NO>
<PG>67-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-12-12 11:19:46 +0000" MODIFIED_BY="Katie Carmichael">
<STUDY DATA_SOURCE="PUB" ID="STD-Shimizu-1988" MODIFIED="2013-12-12 11:19:46 +0000" MODIFIED_BY="Katie Carmichael" NAME="Shimizu 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-12-12 11:19:46 +0000" MODIFIED_BY="Katie Carmichael" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shimizu A, Yamamoto J, Yamada Y, Tanaka M, Kawasaki T</AU>
<TI>The antiepileptic effect of zonisamide on patients with refractory seizures and its side effects</TI>
<SO>Japanese Journal of Psychiatry and Neurology</SO>
<YR>1988</YR>
<VL>42</VL>
<NO>3</NO>
<PG>583</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-10-08 10:09:40 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1988" MODIFIED="2013-10-08 10:09:40 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-10-08 10:09:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson TJ, Donaldson IM, McConnell H, Pollock M, Dobbs BR</AU>
<TI>Zonisamide: comparison with sodium valproate as additional treatment in refractory seizures</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1988</YR>
<VL>101</VL>
<NO>854</NO>
<PG>611</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-11-04 09:35:52 +0000" MODIFIED_BY="Katie Carmichael"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-12-12 11:20:31 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-12-12 11:20:31 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Baulac-2007" MODIFIED="2013-06-18 22:50:45 +0100" MODIFIED_BY="Katie Carmichael" NAME="Baulac 2007" TYPE="JOURNAL_ARTICLE">
<AU>Baulac M, Leppik IE</AU>
<TI>Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures</TI>
<SO>Epilepsy Research</SO>
<YR>2007</YR>
<VL>75</VL>
<PG>75-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-British-National-Formulary" MODIFIED="2013-10-29 15:03:08 +0000" MODIFIED_BY="Katie Carmichael" NAME="British National Formulary" TYPE="OTHER">
<TI>British National Formulary</TI>
<SO>www.bnf.org</SO>
<YR>(accessed May 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cockerell-1995" NAME="Cockerell 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD</AU>
<TI>Remission of epilepsy: results from the National General Practice Study of Epilepsy</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>346</VL>
<PG>140-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hauser-1993" NAME="Hauser 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hauser WA, Annegers JF, Kurland LT</AU>
<TI>Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 - 1984</TI>
<SO>Epilepsia</SO>
<YR>1993</YR>
<VL>34</VL>
<PG>453-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-10-17 09:28:32 +0100" MODIFIED_BY="Katie Carmichael" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2009" MODIFIED="2013-10-17 11:14:24 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2009" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leppik-2004" MODIFIED="2013-12-12 11:20:02 +0000" MODIFIED_BY="Katie Carmichael" NAME="Leppik 2004" TYPE="JOURNAL_ARTICLE">
<AU>Leppik IE</AU>
<TI>Zonisamide: chemistry, mechanism of action, and pharmacokinetics</TI>
<SO>Seizure</SO>
<YR>2004</YR>
<VL>S13</VL>
<PG>S5-S9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marson-2000" MODIFIED="2013-10-09 14:34:12 +0100" MODIFIED_BY="[Empty name]" NAME="Marson 2000" TYPE="COCHRANE_REVIEW">
<AU>Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW</AU>
<TI>Carbamazepine versus valproate monotherapy for epilepsy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-10-09 14:34:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-09 14:34:12 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001030"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marson-2007" MODIFIED="2013-10-29 15:03:19 +0000" MODIFIED_BY="[Empty name]" NAME="Marson 2007" TYPE="JOURNAL_ARTICLE">
<AU>Marson A, Al-Kharusi A, Alwaidh M, Appleton R, Baker GA, Chadwick DW et al</AU>
<TI>The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial</TI>
<SO>The Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<NO>9566</NO>
<PG>1000-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCullagh-1989" MODIFIED="2013-10-29 15:03:27 +0000" MODIFIED_BY="[Empty name]" NAME="McCullagh 1989" TYPE="BOOK">
<AU>McCullagh P, Nelder JA</AU>
<SO>Generalized Linear Models</SO>
<YR>1989</YR>
<EN>Second</EN>
<PB>Chapman and Hall</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mori-1998" MODIFIED="2013-06-18 22:51:14 +0100" MODIFIED_BY="Katie Carmichael" NAME="Mori 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mori A, Noda Y, Packer L</AU>
<TI>The anticonvulsant zonisamide scavenges free radicals</TI>
<SO>Epilepsy Research</SO>
<YR>1998</YR>
<VL>30</VL>
<PG>153-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sander-1996" NAME="Sander 1996" TYPE="JOURNAL_ARTICLE">
<AU>Sander JW, Shorvon SD</AU>
<TI>Epidemiology of the epilepsies</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1996</YR>
<VL>61</VL>
<NO>5</NO>
<PG>433-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ueda-2003" MODIFIED="2013-12-12 11:20:31 +0000" MODIFIED_BY="Katie Carmichael" NAME="Ueda 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ueda Y, Doi T, Tokumaru J, Willmore LJ</AU>
<TI>Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures</TI>
<SO>Molecular Brain Research</SO>
<YR>2003</YR>
<VL>116</VL>
<NO>1-2</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-10-09 14:33:36 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Chadwick-2005" MODIFIED="2013-10-09 14:33:36 +0100" MODIFIED_BY="[Empty name]" NAME="Chadwick 2005" TYPE="COCHRANE_REVIEW">
<AU>Chadwick DW, Marson AG</AU>
<TI>Zonisamide add-on for drug-resistant partial epilepsy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-10-09 14:33:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-09 14:33:36 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001416.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marson-1996" NAME="Marson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Marson AG, Kadir ZA, Chadwick DW</AU>
<TI>The new antiepileptic drugs: a systematic review of their efficacy and tolerability</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1169-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marson-1997" NAME="Marson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Marson AG, Kadir ZA, Hutton JL, Chadwick DW</AU>
<TI>The new antiepileptic drugs: a systematic review of their efficacy and tolerability</TI>
<SO>Epilepsia</SO>
<YR>1997</YR>
<VL>38</VL>
<NO>8</NO>
<PG>859-80</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-08-28 14:58:34 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Lu-2011" MODIFIED="2012-08-28 14:58:34 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 2011" TYPE="JOURNAL_ARTICLE">
<AU>Lu Y, Xiao Z, Yu W, Xiao F, Xiao Z, Hu Y, et al</AU>
<TI>Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>4</NO>
<PG>221-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohtahara-2007" MODIFIED="2010-06-18 13:50:10 +0100" MODIFIED_BY="[Empty name]" NAME="Ohtahara 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ohtahara S, Iinuma K, Fujiwara T, Yamatogi Y</AU>
<TI>Single-blind and controlled comparative study of lamotrigine with zonisamide for refractory pediatric epilepsy</TI>
<SO>Journal of the Japan Epilepsy Society</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>4</NO>
<PG>425-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosati-2010" MODIFIED="2011-02-03 14:00:29 +0000" MODIFIED_BY="[Empty name]" NAME="Rosati 2010" TYPE="JOURNAL_ARTICLE">
<AU>Rosati A, Pellacani S, van Maanen R, Segieth J, Guerrini R</AU>
<TI>Design and current status of the CATZ Study: a phase III, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of adjunctive zonisamide in pediatric patients with partial-onset seizures [abstract no: p236]</TI>
<SO>Epilepsia</SO>
<YR>2010</YR>
<VL>51 Suppl 4</VL>
<PG>71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wroe-2008" MODIFIED="2010-06-18 13:51:48 +0100" MODIFIED_BY="[Empty name]" NAME="Wroe 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wroe SJ, Yeates AB, Marshall A</AU>
<TI>Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2008</YR>
<VL>118</VL>
<NO>2</NO>
<PG>87-93</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-12-12 11:45:14 +0000" MODIFIED_BY="Katie Carmichael">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-12-12 11:45:14 +0000" MODIFIED_BY="Katie Carmichael" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-10-29 15:00:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brodie-2005">
<CHAR_METHODS MODIFIED="2013-10-29 15:00:14 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, parallel-group study<BR/>Allocation concealment using telephone randomisation<BR/>Random permuted blocks of 6 per participating centre<BR/>Blinded using identical tablets and packaging<BR/>12 week pre-randomisation baseline period, 24-week treatment period including 6-week dose titration<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-29 15:00:18 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre study, 49 centres in Europe and 5 in South Africa<BR/>351 participants. At least 12 seizures during 12-week baseline period, with no period of more than 3 weeks seizure-free<BR/>Taking 1 to 3 AEDs<BR/>Aged 12 to 77<BR/>51% male</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-29 15:00:19 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo, 100 mg, 300 mg or 500 mg placebo, randomised in 2:1:1:2 ratio</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-29 15:00:20 +0000" MODIFIED_BY="[Empty name]">
<P>Reduction in seizure frequency, proportion with a 50% or greater reduction in seizure frequency<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-12 11:45:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Faught-2001">
<CHAR_METHODS MODIFIED="2013-12-12 11:45:14 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Comments (Statistician)&lt;/p&gt;&lt;p&gt;Is this a randomised division?&lt;/p&gt;&lt;p&gt;Response from review authors:&lt;/p&gt;&lt;p&gt;Yes it says so above&lt;/p&gt;" NOTES_MODIFIED="2013-12-12 11:45:14 +0000" NOTES_MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, parallel-group study. 2 treatment arms: 1 placebo and 1 zonisamide<BR/>Randomisation concealment by allocated sequentially numbered, sealed packages. Random list generated by random permuted blocks. Blinding by identical packing and tablets<BR/>All participants received placebo during 28-day prospective baseline. Treatment period was 12 weeks. Participants receiving zonisamide were divided into 2 groups, 1 (group B1) of which received 100 mg/day during weeks 1 to 5, the second (group B2) of which received 100 mg/day during week 1 followed by 200 mg/day during weeks 2 to 5. Both groups received an escalating dose of zonisamide for weeks 5 to 7 followed by 400 mg/day during weeks 8 to 12</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-29 15:00:41 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre (20) US study<BR/>Total randomised: 203 participants between April 1994 and March 1996 with at least 4 partial seizures/month taking 1 or 2 AEDs, 85 to placebo, 60 to group B1, 58 to group B2<BR/>Ages 13 to 68 years, 104 male, 99 female<BR/>Median monthly seizure frequency for the randomised groups during baseline ranged between 11.2 and 13 seizures/month</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-29 15:00:43 +0000" MODIFIED_BY="[Empty name]">
<P>Zonisamide 400 mg/day or placebo (weeks 8 to 12)<BR/>Zonisamide 100 mg/day or 200 mg/day or placebo (weeks 1 to 5)<BR/>All treatments and packaging were identical</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-29 15:00:45 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: median percentage reduction from baseline of all partial seizures<BR/>Secondary: proportion of participants showing a 50% reduction in all partial seizures from baseline<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-29 15:00:45 +0000" MODIFIED_BY="[Empty name]">
<P>Of the randomised participants 8 failed to complete week 5 in the placebo group, 15 in the zonisamide group<BR/>By the end of week 12, 13 participants had withdrawn from the placebo group, 23 from zonisamide</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-29 15:01:00 +0000" MODIFIED_BY="Katie Carmichael" STUDY_ID="STD-Lu-2011">
<CHAR_METHODS MODIFIED="2013-10-29 15:00:55 +0000" MODIFIED_BY="Katie Carmichael">
<P>Randomised, double-blind, placebo-controlled, parallel trial. 12-week baseline phase, 4-week titration phase, 12-week stable treatment phase. Placebo or zonisamide treatment interventions</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-29 15:00:57 +0000" MODIFIED_BY="Katie Carmichael">
<P>Single centre in China. 104 participants randomised, 53 received zonisamide (29 M:24 F) and 51 received placebo (32 M: 19 F). Mean age of zonisamide group = 36.83 years +/- 10.77 and mean age in placebo group = 29.81 years +/- 8.24. All participants had simple partial seizures, complex partial seizures or secondary generalised seizures</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-29 15:00:58 +0000" MODIFIED_BY="Katie Carmichael">
<P>Placebo or zonisamide (titrated to 300 mg/day or 400 mg/day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-29 15:01:00 +0000" MODIFIED_BY="Katie Carmichael">
<P>The following outcomes were measured:</P>
<P>1. Responder rate (50% or greater reduction in seizures frequency during treatment phase compared to baseline)</P>
<P>2. Seizure freedom</P>
<P>3. Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-29 15:01:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sackellares-2004">
<CHAR_METHODS MODIFIED="2013-10-29 15:01:14 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, parallel-group study<BR/>2 treatment arms, 1 placebo, 1 zonisamide. The initial target dose of zonisamide was 7 mg/kg/day, but when it became apparent that this was associated with a significant incidence of adverse effects, it was titrated over the first 4 weeks to 400 mg/day. Thereafter a non-blinded observer recommended dose adjustments to obtain plasma levels of 20 to 30 µg/ml. Median dosage in this group was 400 mg/day (range 200 to 600 mg/day)<BR/>Randomisation concealment by allocated sequentially numbered, sealed packages. Random list generated by random permuted blocks. Blinding by identical packing and tablets<BR/>Baseline was variable, between 8 and 12 weeks, being extended if frequency was below 4 partial seizures/month<BR/>Treatment period was 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-29 15:01:16 +0000" MODIFIED_BY="[Empty name]">
<P>Conducted at 4 US centres between August 1983 and July 1986<BR/>Total randomised: 152 participants, all with 4 or more partial seizures/month while taking 1 or 2 AEDs. 78 were randomised to zonisamide, 74 to placebo<BR/>Age 17 to 67 years, 101 male 51 female<BR/>Median monthly seizure frequency pre-baseline: 7.5 zonisamide, 11.1 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-29 15:01:16 +0000" MODIFIED_BY="[Empty name]">
<P>Zonisamide median dosage 400 mg/day (100 mg capsules)<BR/>Placebo<BR/>Treatments and packaging were identical</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-29 15:01:17 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: median percentage reduction in seizure frequency of all partial seizures from baseline<BR/>Secondary: proportion of participants with a 50% reduction in all partial seizures from baseline</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-29 15:01:19 +0000" MODIFIED_BY="[Empty name]">
<P>Because of the variable baseline periods, baseline seizure frequency was recalculated for the 8 weeks immediately before entry into the treatment period<BR/>14 people failed to complete the 12-week treatment period in the zonisamide group, 7 in the placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-29 15:01:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmidt-1993">
<CHAR_METHODS MODIFIED="2013-10-29 15:01:33 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, parallel group study<BR/>2 treatment arms, 1 placebo, 1 zonisamide. The initial target dose of zonisamide was 7 mg/kg/day, but when it became apparent that this was associated with a significant incidence of adverse effects, it was titrated over the first 4 weeks to 400 mg/day. Thereafter a non-blinded observer recommended dose adjustments to obtain plasma levels of 20 to 30 µg/ml. Median dosage in this group was 400 mg/day<BR/>Randomisation concealment by allocated sequentially numbered, sealed packages. Random list generated by random permuted blocks. Blinding by identical packing and tablets<BR/>Baseline was variable, between 8 and 12 weeks, being extended if frequency was below 4 partial seizures/month<BR/>Treatment period was 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-29 15:01:36 +0000" MODIFIED_BY="[Empty name]">
<P>Participants from 10 European centres recruited between June 1984 and October 1986<BR/>Total randomised: 144 participants, all with 4 or more partial seizures/month while taking 1 or 2 AEDs. 73 were randomised to zonisamide, 71 to placebo<BR/>Age 17 to 60 years, 85 male 59 female<BR/>Median monthly seizure frequency pre-baseline: 11.3 zonisamide, 11.0 placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-29 15:01:37 +0000" MODIFIED_BY="[Empty name]">
<P>Zonisamide median dosage 400 mg/day (100 mg capsules)<BR/>Placebo<BR/>Treatments and packaging were identical</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-29 15:01:37 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: median percentage reduction in seizure frequency of all partial seizures from baseline<BR/>Secondary: proportion of participants with a 50% reduction in all partial seizures from baseline</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-29 15:01:39 +0000" MODIFIED_BY="[Empty name]">
<P>Because of the variable baseline periods, baseline seizure frequency was recalculated for the 8 weeks immediately before entry into the treatment period<BR/>7 people failed to complete the 12-week treatment period in the zonisamide group, 2 in the placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AED: antiepileptic drug<BR/>F: female<BR/>ITT: intention-to-treat<BR/>M: male<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-10-29 15:01:47 +0000" MODIFIED_BY="Katie Carmichael" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-10-29 15:01:47 +0000" MODIFIED_BY="Katie Carmichael" STUDY_ID="STD-Shimizu-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-29 15:01:47 +0000" MODIFIED_BY="Katie Carmichael">
<P>No control group was used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-10-29 15:01:49 +0000" MODIFIED_BY="Katie Carmichael" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-10-29 15:01:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1988">
<CHAR_METHODS MODIFIED="2013-10-08 10:12:13 +0100" MODIFIED_BY="[Empty name]">
<P>No details</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-08 10:12:16 +0100" MODIFIED_BY="[Empty name]">
<P>No details</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-29 15:01:49 +0000" MODIFIED_BY="[Empty name]">
<P>Zonisamide add-on versus sodium valproate add-on</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-08 10:12:41 +0100" MODIFIED_BY="[Empty name]">
<P>No details</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-08 10:12:46 +0100" MODIFIED_BY="[Empty name]">
<P>No details</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-11-04 09:35:52 +0000" MODIFIED_BY="Katie Carmichael" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-10-29 15:01:44 +0000" MODIFIED_BY="Katie Carmichael">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-10-29 15:01:41 +0000" MODIFIED_BY="Katie Carmichael" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:00:23 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Brodie-2005">
<DESCRIPTION>
<P>"Patients were randomised sequentially in blocks of six"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:00:50 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Faught-2001">
<DESCRIPTION>
<P>"Randomization codes were generated centrally, with separate randomization sequences for each site."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-08 12:25:23 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2011">
<DESCRIPTION>
<P>No information given other than "zonisamide and placebo were assigned to our centre in a ratio of 1:1" (page 223)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:01:21 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Sackellares-2004">
<DESCRIPTION>
<P>"Randomisation codes were generated by the study sponsor". "Each patient who qualified to receive double-blind treatment was assigned a randomisation number and given zonisamide or placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:01:41 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>"Patients were randomised sequentially in blocks of four"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-10-29 15:01:41 +0000" MODIFIED_BY="Katie Carmichael" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:00:23 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Brodie-2005">
<DESCRIPTION>
<P>Insufficient details were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:00:50 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Faught-2001">
<DESCRIPTION>
<P>"Each investigator had a sealed copy of the code to be opened in an emergency. Otherwise, assignments were not revealed until all patients at all sites had completed the study." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:01:03 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Lu-2011">
<DESCRIPTION>
<P>"Random allocation of patients to their treatment group was concealed via the use of numbered containers" Comment: it is not explicitly stated whether the containers were opaque or not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-17 10:26:01 +0100" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Sackellares-2004">
<DESCRIPTION>
<P>"Random allocation of patients to their treatment groups was concealed via the use of numbered containers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:01:41 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>Insufficient details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-10-29 15:01:41 +0000" MODIFIED_BY="Katie Carmichael" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-29 15:00:23 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Brodie-2005">
<DESCRIPTION>
<P>"Treatments were blinded using a double dummy technique throughout the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-29 15:00:51 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Faught-2001">
<DESCRIPTION>
<P>Insufficient detail was provided about blinding of personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-29 15:01:04 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Lu-2011">
<DESCRIPTION>
<P>"Investigators were blind to treatment each patient received until the end of the study" and "Zonisamide and placebo tablets had the same size, colour and shape. The tablets were randomly numbered by the study sponsors"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-29 15:01:22 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Sackellares-2004">
<DESCRIPTION>
<P>This study was deemed to be at low risk of performance bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-29 15:01:41 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>Insufficient details were provided about blinding of personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-10-29 15:01:42 +0000" MODIFIED_BY="Katie Carmichael" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-29 15:00:26 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Brodie-2005">
<DESCRIPTION>
<P>Insufficient details about blinding of outcome assessors was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-29 15:00:51 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Faught-2001">
<DESCRIPTION>
<P>Insufficient detail was provided about blinding of outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-29 15:01:04 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2011">
<DESCRIPTION>
<P>It is unclear whether the investigators who were blinded were also the outcome assessors or not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-29 15:01:25 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Sackellares-2004">
<DESCRIPTION>
<P>This study was deemed to be at low risk of detection bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-29 15:01:42 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>Blinding of outcome assessors was not detailed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-10-29 15:01:43 +0000" MODIFIED_BY="Katie Carmichael" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-29 15:00:30 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Brodie-2005">
<DESCRIPTION>
<P>A modified ITT analysis was conducted as "all patients who received at least one dose of study drug were included in the safety analysis". 4 participants not included in the analysis were spread fairly evenly among groups (1 participant lost from 2 groups, 2 participants lost from 1 group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-29 15:00:52 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Faught-2001">
<DESCRIPTION>
<P>The analysis for "the primary populations was a modified ITT" as it included participants who had received at least one dose of study medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-29 15:01:07 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Lu-2011">
<DESCRIPTION>
<P>One patient was lost from each group, therefore missing data were balanced between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-29 15:01:26 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Sackellares-2004">
<DESCRIPTION>
<P>Insufficient or unclear details were provided with regard to attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-29 15:01:43 +0000" MODIFIED_BY="Katie Carmichael" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>A modified ITT analysis was conducted including patients who had received "at least 7 days of treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-10-29 15:01:43 +0000" MODIFIED_BY="Katie Carmichael" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:00:31 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Brodie-2005">
<DESCRIPTION>
<P>This study was deemed to be at a low risk of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:00:52 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Faught-2001">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:01:07 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Lu-2011">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:01:26 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Sackellares-2004">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:01:43 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>This study was deemed to be at low risk of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-10-29 15:01:44 +0000" MODIFIED_BY="Katie Carmichael" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:00:32 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Brodie-2005">
<DESCRIPTION>
<P>Allocation to groups led to different durations of stable-dose phase</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:00:53 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Faught-2001">
<DESCRIPTION>
<P>No evidence of any other source of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:01:07 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Lu-2011">
<DESCRIPTION>
<P>Both providers of zonisamide were manufacturers of the drug</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:01:26 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Sackellares-2004">
<DESCRIPTION>
<P>Baseline period was extended if the frequency of seizures did not meet a prespecified threshold</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-29 15:01:44 +0000" MODIFIED_BY="Katie Carmichael" RESULT="YES" STUDY_ID="STD-Schmidt-1993">
<DESCRIPTION>
<P>Baseline period was extended if the frequency of seizures did not meet a prespecified threshold</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-12-12 11:54:50 +0000" MODIFIED_BY="Katie Carmichael">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-11-04 09:42:41 +0000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-02-04 15:15:18 +0000" MODIFIED_BY="Grade Profiler">Zonisamide versus placebo for drug-resistant partial epilepsy</TITLE>
<TABLE COLS="7" ROWS="43">
<TR>
<TD COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Zonisamide versus placebo for drug-resistant partial epilepsy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population:</B> patients with drug-resistant partial epilepsy<BR/>
<B>Settings: </B>hospital out-patient setting<BR/>
<B>Intervention:</B> zonisamide versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Zonisamide versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>50% responder rate - whole treatment period - any dose</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.92 </B>
<BR/>(1.52 to 2.42)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>949<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>3 out of 5 studies found a non-significant effect of zonisamide on responder rate but the combined overall effect was statistically significant</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>191 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>367 per 1000</B>
<BR/>(290 to 462)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>175 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>336 per 1000</B>
<BR/>(266 to 424)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Withdrawal rates - any dose</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.47 </B>
<BR/>(1.07 to 2.01)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>949<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>No study produced a statistically significant effect of zonisamide on withdrawal rates independently but a statistically significant effect was found overall</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>113 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>166 per 1000</B>
<BR/>(121 to 227)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>95 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>140 per 1000</B>
<BR/>(102 to 191)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects - ataxia</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>3.77 </B>
<BR/>(1.28 to 11.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>494<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>No study found a statistically significant effect of zonisamide on ataxia independently, but there was a significant effect when study data were combined</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>26 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
<BR/>(34 to 294)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>24 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>90 per 1000</B>
<BR/>(31 to 267)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects - dizziness</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>1.46 </B>
<BR/>(0.88 to 2.44)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>949<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>No study found a statistically significant effect of zonisamide on dizziness independently</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>88 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>128 per 1000</B>
<BR/>(77 to 215)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>118 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>172 per 1000</B>
<BR/>(104 to 288)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects - nausea</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>1.21 </B>
<BR/>(0.61 to 2.4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>598<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>No study found a statistically significant effect of zonisamide on nausea independently</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>76 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>91 per 1000</B>
<BR/>(46 to 181)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>69 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>83 per 1000</B>
<BR/>(42 to 166)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects - fatigue</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>1.41 </B>
<BR/>(0.76 to 2.62)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>598<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>No study found a statistically significant effect of zonisamide on fatigue independently</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>86 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>122 per 1000</B>
<BR/>(66 to 226)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>79 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>111 per 1000</B>
<BR/>(60 to 207)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects - somnolence</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>1.83 </B>
<BR/>(1.08 to 3.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>949<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>4 out of 5 studies found no statistically significant difference in the occurrence of somnolence between the zonisamide group and the control group</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>75 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>138 per 1000</B>
<BR/>(81 to 234)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>118 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>216 per 1000</B>
<BR/>(127 to 367)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects - agitation/irritability</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>2.35 </B>
<BR/>(1.05 to 5.27)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>598<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1 out of 4 studies found a significant effect of zonisamide on agitation/irritability and there was a statistically significant effect overall</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>43 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>101 per 1000</B>
<BR/>(45 to 227)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>103 per 1000</B>
<BR/>(46 to 232)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects - anorexia</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>2.71 </B>
<BR/>(1.29 to 5.69)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>494<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>None of 3 studies found significant effects of zonisamide on anorexia, but overall there was a significant effect when data were combined</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>62 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>167 per 1000</B>
<BR/>(80 to 351)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>81 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>220 per 1000</B>
<BR/>(104 to 461)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-12-12 11:10:09 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-11-04 09:49:54 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Zonisamide versus placebo</NAME>
<DICH_OUTCOME CHI2="3.845815322746871" CI_END="2.3113164522734344" CI_START="1.6585659230063408" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.957925101995638" ESTIMABLE="YES" EVENTS_1="382" EVENTS_2="148" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.3638594106748708" LOG_CI_START="0.21973273809782767" LOG_EFFECT_SIZE="0.29179607438634925" METHOD="MH" MODIFIED="2013-10-17 11:17:45 +0100" MODIFIED_BY="Katie Carmichael" NO="1" P_CHI2="0.9212642508109335" P_Q="0.7945998771921994" P_Z="2.084523362055307E-15" Q="0.06777802799908692" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1044" TOTAL_2="796" WEIGHT="200.0" Z="7.936210368302231">
<NAME>50% responder rate - whole treatment period</NAME>
<GROUP_LABEL_1>Zonisamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Zonisamide better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5698505755353058" CI_END="2.416320760457259" CI_START="1.5201287385922937" DF="4" EFFECT_SIZE="1.916538188930308" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="76" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.383154585267816" LOG_CI_START="0.1818803695846846" LOG_EFFECT_SIZE="0.2825174774262503" MODIFIED="2013-05-20 13:38:20 +0100" MODIFIED_BY="Katie Carmichael" NO="1" P_CHI2="0.8142004304355804" P_Z="3.7511101380974866E-8" STUDIES="5" TAU2="0.0" TOTAL_1="551" TOTAL_2="398" WEIGHT="100.0" Z="5.502185949444148">
<NAME>Any dose</NAME>
<DICH_DATA CI_END="3.4264627459704102" CI_START="1.478892863229541" EFFECT_SIZE="2.2510822510822512" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="21" LOG_CI_END="0.5348460143359808" LOG_CI_START="0.16993671314932896" LOG_EFFECT_SIZE="0.3523913637426549" MODIFIED="2013-05-20 13:38:20 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.21434952984721228" STUDY_ID="STD-Brodie-2005" TOTAL_1="231" TOTAL_2="120" VAR="0.04594572094572095" WEIGHT="32.10406957461889"/>
<DICH_DATA CI_END="3.061640521492172" CI_START="1.1128775658783359" EFFECT_SIZE="1.8458686440677967" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="16" LOG_CI_END="0.48595419723838884" LOG_CI_START="0.046447387705567396" LOG_EFFECT_SIZE="0.2662007924719781" MODIFIED="2013-05-20 13:38:19 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.2581684755133741" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.06665096174889963" WEIGHT="21.60438369648535"/>
<DICH_DATA CI_END="2.4193875167285412" CI_START="0.9934228911397092" EFFECT_SIZE="1.550314465408805" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="18" LOG_CI_END="0.3837054354962312" LOG_CI_START="-0.0028658369106365485" LOG_EFFECT_SIZE="0.19041979929279734" MODIFIED="2013-05-20 13:38:18 +0100" MODIFIED_BY="Katie Carmichael" ORDER="62" O_E="0.0" SE="0.22707387897045406" STUDY_ID="STD-Lu-2011" TOTAL_1="53" TOTAL_2="51" VAR="0.05156254651068842" WEIGHT="21.308406104489624"/>
<DICH_DATA CI_END="3.2571267560335895" CI_START="0.9288005063804117" EFFECT_SIZE="1.7393162393162394" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.5128346601229804" LOG_CI_START="-0.03207755649282605" LOG_EFFECT_SIZE="0.2403785518150772" MODIFIED="2013-04-03 14:23:20 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.3200841333990994" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.10245385245385245" WEIGHT="14.304352062199587"/>
<DICH_DATA CI_END="4.153917013605427" CI_START="0.9841595134943335" EFFECT_SIZE="2.0219092331768387" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.6184578160090851" LOG_CI_START="-0.006934505007754906" LOG_EFFECT_SIZE="0.3057616555006651" MODIFIED="2013-05-20 13:38:17 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.36735854510720833" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="0.1349523006632848" WEIGHT="10.678788562206554"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2168820182217805" CI_END="2.5404889790378427" CI_START="1.5791401420182551" DF="4" EFFECT_SIZE="2.0029448637328064" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="72" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.4049173152260696" LOG_CI_START="0.1984206735196737" LOG_EFFECT_SIZE="0.30166899437287165" MODIFIED="2013-10-17 11:17:45 +0100" MODIFIED_BY="Katie Carmichael" NO="2" P_CHI2="0.6959397751426613" P_Z="1.0247196990415222E-8" STUDIES="5" TAU2="0.0" TOTAL_1="493" TOTAL_2="398" WEIGHT="100.0" Z="5.726585762725568">
<NAME>300 to 500 mg zonisamide</NAME>
<DICH_DATA CI_END="3.7387009432380784" CI_START="1.5979912916854728" EFFECT_SIZE="2.444260941370768" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="21" LOG_CI_END="0.5727207275517042" LOG_CI_START="0.20357440828006845" LOG_EFFECT_SIZE="0.38814756791588634" MODIFIED="2013-01-31 11:58:48 +0000" MODIFIED_BY="[Empty name]" ORDER="52997" O_E="0.0" SE="0.21683837524390961" STUDY_ID="STD-Brodie-2005" TOTAL_1="173" TOTAL_2="120" VAR="0.047018880978418554" WEIGHT="31.330971725942327"/>
<DICH_DATA CI_END="3.061640521492172" CI_START="1.1128775658783359" EFFECT_SIZE="1.8458686440677967" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="16" LOG_CI_END="0.48595419723838884" LOG_CI_START="0.046447387705567396" LOG_EFFECT_SIZE="0.2662007924719781" MODIFIED="2013-01-30 12:03:05 +0000" MODIFIED_BY="Katie Carmichael" ORDER="52998" O_E="0.0" SE="0.2581684755133741" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.06665096174889963" WEIGHT="23.500767137641787"/>
<DICH_DATA CI_END="2.4193875167285412" CI_START="0.9934228911397092" EFFECT_SIZE="1.550314465408805" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="18" LOG_CI_END="0.3837054354962312" LOG_CI_START="-0.0028658369106365485" LOG_EFFECT_SIZE="0.19041979929279734" MODIFIED="2012-11-20 11:39:27 +0000" MODIFIED_BY="Katie Carmichael" ORDER="63" O_E="0.0" SE="0.22707387897045406" STUDY_ID="STD-Lu-2011" TOTAL_1="53" TOTAL_2="51" VAR="0.05156254651068842" WEIGHT="23.17880930884322"/>
<DICH_DATA CI_END="4.388286098238336" CI_START="0.9261837752339054" EFFECT_SIZE="2.016025641025641" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.6422949340430062" LOG_CI_START="-0.03330283118935393" LOG_EFFECT_SIZE="0.3044960514268261" ORDER="53000" O_E="0.0" SE="0.39684947156036177" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.15748950307773837" WEIGHT="10.373303603295609"/>
<DICH_DATA CI_END="4.153917013605427" CI_START="0.9841595134943335" EFFECT_SIZE="2.0219092331768387" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.6184578160090851" LOG_CI_START="-0.006934505007754906" LOG_EFFECT_SIZE="0.3057616555006651" MODIFIED="2013-01-22 16:21:34 +0000" MODIFIED_BY="[Empty name]" ORDER="52999" O_E="0.0" SE="0.36735854510720833" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="0.1349523006632848" WEIGHT="11.616148224277069"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.077527011425017" CI_END="2.7877691030869975" CI_START="1.776251752187409" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2252594801623027" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.4452568004848594" LOG_CI_START="0.24950451934647488" LOG_EFFECT_SIZE="0.34738065991566713" METHOD="MH" MODIFIED="2013-10-17 11:17:54 +0100" MODIFIED_BY="Katie Carmichael" NO="2" P_CHI2="0.5449364003014388" P_Q="1.0" P_Z="3.4938165388992917E-12" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="551" TOTAL_2="398" WEIGHT="100.0" Z="6.9562773767028965">
<NAME>50% responder rate - best-case</NAME>
<GROUP_LABEL_1>Zonisamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Zonisamide better</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5337415643632033" CI_START="1.5301036997986572" EFFECT_SIZE="2.3252937538651826" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="21" LOG_CI_END="0.5482347847646761" LOG_CI_START="0.18472086527784373" LOG_EFFECT_SIZE="0.3664778250212599" ORDER="4" O_E="0.0" SE="0.21352987572948753" STUDY_ID="STD-Brodie-2005" TOTAL_1="231" TOTAL_2="120" VAR="0.045595007829050384" WEIGHT="32.10406957461889"/>
<DICH_DATA CI_END="3.4679580727189236" CI_START="1.291087716151135" EFFECT_SIZE="2.1159957627118646" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="16" LOG_CI_END="0.5400738382572051" LOG_CI_START="0.11095574911871511" LOG_EFFECT_SIZE="0.3255147936879601" MODIFIED="2013-01-22 13:49:11 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.25206608972874844" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.06353731359114147" WEIGHT="21.60438369648535"/>
<DICH_DATA CI_END="2.490360400189349" CI_START="1.032818266563181" EFFECT_SIZE="1.6037735849056605" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.3962622019099295" LOG_CI_START="0.014023910317077897" LOG_EFFECT_SIZE="0.20514305611350372" MODIFIED="2012-11-20 11:40:44 +0000" MODIFIED_BY="Katie Carmichael" ORDER="64" O_E="0.0" SE="0.22452866459169996" STUDY_ID="STD-Lu-2011" TOTAL_1="53" TOTAL_2="51" VAR="0.050413121223332094" WEIGHT="21.308406104489624"/>
<DICH_DATA CI_END="5.036148288673646" CI_START="1.608489514535276" EFFECT_SIZE="2.8461538461538463" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="12" LOG_CI_END="0.7020985093636537" LOG_CI_START="0.20641823415666288" LOG_EFFECT_SIZE="0.45425837176015826" MODIFIED="2013-01-22 14:26:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.2911650473135207" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.08477708477708477" WEIGHT="14.304352062199587"/>
<DICH_DATA CI_END="5.092640820317092" CI_START="1.280841957599654" EFFECT_SIZE="2.5539906103286385" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.7069430468309823" LOG_CI_START="0.10749554568790207" LOG_EFFECT_SIZE="0.4072192962594422" MODIFIED="2013-01-22 16:21:40 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.3521184294844322" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="0.12398738838258305" WEIGHT="10.678788562206554"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.822837678006916" CI_END="1.745649157142574" CI_START="1.1624005922850664" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4244801206701536" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="103" I2="48.86765947802319" I2_Q="100.0" ID="CMP-001.03" LOG_CI_END="0.24195696306505948" LOG_CI_START="0.0653558225787388" LOG_EFFECT_SIZE="0.15365639282189916" METHOD="MH" MODIFIED="2013-10-17 11:18:00 +0100" MODIFIED_BY="Katie Carmichael" NO="3" P_CHI2="0.09828792117224683" P_Q="0.0" P_Z="6.481184254752347E-4" Q="2.863507048278492E-31" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="551" TOTAL_2="398" WEIGHT="100.00000000000001" Z="3.4106347795481975">
<NAME>50% responder rate - worst-case</NAME>
<GROUP_LABEL_1>Zonisamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Zonisamide better</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.238120943032466" CI_START="1.4258797121839264" EFFECT_SIZE="2.1487603305785123" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="22" LOG_CI_END="0.5102930655139319" LOG_CI_START="0.15408288979480372" LOG_EFFECT_SIZE="0.33218797765436786" ORDER="4" O_E="0.0" SE="0.20923962048622338" STUDY_ID="STD-Brodie-2005" TOTAL_1="231" TOTAL_2="120" VAR="0.04378121878121879" WEIGHT="24.997834554175892"/>
<DICH_DATA CI_END="1.4970295632075805" CI_START="0.6928116430692871" EFFECT_SIZE="1.0184102863822326" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="29" LOG_CI_END="0.17523037683680362" LOG_CI_START="-0.1593848223789101" LOG_EFFECT_SIZE="0.007922777228946763" MODIFIED="2013-01-22 13:57:39 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.19655462439126" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.0386337203695893" WEIGHT="29.10441084963336"/>
<DICH_DATA CI_END="2.2628929050553324" CI_START="0.9532644695117078" EFFECT_SIZE="1.4687189672293943" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" LOG_CI_END="0.3546640007757236" LOG_CI_START="-0.020786593889174584" LOG_EFFECT_SIZE="0.16693870344327447" MODIFIED="2012-11-20 11:42:06 +0000" MODIFIED_BY="Katie Carmichael" ORDER="65" O_E="0.0" SE="0.22054153781657843" STUDY_ID="STD-Lu-2011" TOTAL_1="53" TOTAL_2="51" VAR="0.04863856990250129" WEIGHT="16.71748631674263"/>
<DICH_DATA CI_END="1.8570089511589325" CI_START="0.6498279644688725" EFFECT_SIZE="1.098515519568151" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" LOG_CI_END="0.2688139971321131" LOG_CI_START="-0.18720160331236707" LOG_EFFECT_SIZE="0.040806196909873034" MODIFIED="2013-01-22 14:27:15 +0000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.2678658210147154" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.07175209806788754" WEIGHT="16.833695258368447"/>
<DICH_DATA CI_END="2.3801607829889617" CI_START="0.7098162921286953" EFFECT_SIZE="1.2997987927565393" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.3766062952104525" LOG_CI_START="-0.1488540366869485" LOG_EFFECT_SIZE="0.11387612926175199" MODIFIED="2013-01-22 16:21:50 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.30865800002712573" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="0.09526976098074515" WEIGHT="12.34657302107968"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="91" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-11-04 09:49:54 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="231" TOTAL_2="360" WEIGHT="0.0" Z="0.0">
<NAME>50% responder rate - dose effect Brodie 2005</NAME>
<GROUP_LABEL_1>Zonisamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Zonisamide better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="21" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>100 mg per day</NAME>
<DICH_DATA CI_END="2.972633861621403" CI_START="0.9770811017764928" EFFECT_SIZE="1.7042606516290726" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.47314142058409786" LOG_CI_START="-0.010069386545121746" LOG_EFFECT_SIZE="0.23153601701948806" ORDER="53009" O_E="0.0" SE="0.2838404200397755" STUDY_ID="STD-Brodie-2005" TOTAL_1="57" TOTAL_2="120" VAR="0.08056538404835618" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="21" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>300 mg per day</NAME>
<DICH_DATA CI_END="3.3050152483219897" CI_START="1.1373171366986967" EFFECT_SIZE="1.9387755102040816" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.5191734675272027" LOG_CI_START="0.05588158299346554" LOG_EFFECT_SIZE="0.2875275252603341" ORDER="53010" O_E="0.0" SE="0.27213994630693206" STUDY_ID="STD-Brodie-2005" TOTAL_1="56" TOTAL_2="120" VAR="0.07406015037593985" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="55" EVENTS_2="21" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>500 mg per day</NAME>
<DICH_DATA CI_END="4.110082920639802" CI_START="1.7259757245793708" EFFECT_SIZE="2.6634382566585955" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="21" LOG_CI_END="0.6138505838257116" LOG_CI_START="0.2370346831779365" LOG_EFFECT_SIZE="0.425442633501824" ORDER="53011" O_E="0.0" SE="0.2213435253092939" STUDY_ID="STD-Brodie-2005" TOTAL_1="118" TOTAL_2="120" VAR="0.048992956196346034" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="78" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-10-17 11:19:02 +0100" MODIFIED_BY="Katie Carmichael" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="236" TOTAL_2="255" WEIGHT="0.0" Z="0.0">
<NAME>50% responder rate - dose effect Faught 2001</NAME>
<GROUP_LABEL_1>zonismide</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Zonisamide better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="11" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>100 mg per day</NAME>
<DICH_DATA CI_END="3.907146462689774" CI_START="0.9551526985845729" EFFECT_SIZE="1.9318181818181819" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.5918596914259004" LOG_CI_START="-0.019927192969689797" LOG_EFFECT_SIZE="0.2859662492281053" ORDER="53012" O_E="0.0" SE="0.3593666442878888" STUDY_ID="STD-Faught-2001" TOTAL_1="60" TOTAL_2="85" VAR="0.12914438502673797" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="11" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>200 mg per day</NAME>
<DICH_DATA CI_END="4.475105818320715" CI_START="1.1462808251580896" EFFECT_SIZE="2.2648902821316614" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.6508033090976124" LOG_CI_START="0.059291027645196295" LOG_EFFECT_SIZE="0.3550471683714043" ORDER="53013" O_E="0.0" SE="0.34745724215816515" STUDY_ID="STD-Faught-2001" TOTAL_1="58" TOTAL_2="85" VAR="0.12072653512815783" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="46" EVENTS_2="19" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-02-01 15:22:43 +0000" MODIFIED_BY="Katie Carmichael" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>400 mg per day</NAME>
<DICH_DATA CI_END="2.751585898712891" CI_START="1.1053484921910264" EFFECT_SIZE="1.743978590544157" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="19" LOG_CI_END="0.43958307511726735" LOG_CI_START="0.043499223156557604" LOG_EFFECT_SIZE="0.24154114913691244" ORDER="53014" O_E="0.0" SE="0.232661615288409" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.05413142722861164" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.699179664054025" CI_END="1.9412055979510436" CI_START="1.239814998343817" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.551365790266332" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="90" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.2880715350416318" LOG_CI_START="0.09335688581339172" LOG_EFFECT_SIZE="0.19071421042751174" METHOD="MH" MODIFIED="2013-11-04 09:39:23 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8137004723867705" P_Q="0.6221377802590169" P_Z="1.2333910908675775E-4" Q="0.24287437880486423" RANDOM="NO" SCALE="48.77465130711193" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1045" TOTAL_2="796" WEIGHT="200.0" Z="3.8393925188419145">
<NAME>Withdrawal rates</NAME>
<GROUP_LABEL_1>Zonisamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo worse</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Zonisamide worse</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8546757377106993" CI_END="2.0135236794935656" CI_START="1.0678693243973114" DF="3" EFFECT_SIZE="1.4663492664705713" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="45" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.3039567413747487" LOG_CI_START="0.028518111151910955" LOG_EFFECT_SIZE="0.16623742626332982" MODIFIED="2013-01-30 13:53:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6031099513751972" P_Z="0.01799009757367214" STUDIES="5" TAU2="0.0" TOTAL_1="551" TOTAL_2="398" WEIGHT="100.0" Z="2.3658218754222107">
<NAME>Any dose</NAME>
<DICH_DATA CI_END="2.045151261174557" CI_START="0.8682833021309524" EFFECT_SIZE="1.3325804630152456" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="23" LOG_CI_END="0.3107254343306767" LOG_CI_START="-0.06133855077061313" LOG_EFFECT_SIZE="0.12469344178003182" ORDER="4" O_E="0.0" SE="0.21855222659492726" STUDY_ID="STD-Brodie-2005" TOTAL_1="231" TOTAL_2="120" VAR="0.047765075749600434" WEIGHT="55.43158178369201"/>
<DICH_DATA CI_END="2.3698070205380057" CI_START="0.6853774675902221" EFFECT_SIZE="1.274445893089961" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="13" LOG_CI_END="0.3747129817367704" LOG_CI_START="-0.16407017749892353" LOG_EFFECT_SIZE="0.10532140211892348" ORDER="3" O_E="0.0" SE="0.316483894754698" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.10016205563910276" WEIGHT="27.672850315213847"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-22 14:04:12 +0000" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.0" STUDY_ID="STD-Lu-2011" TOTAL_1="53" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.438046845544749" CI_START="0.8112269000703745" EFFECT_SIZE="1.8974358974358974" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6471918820902689" LOG_CI_START="-0.09085765668131479" LOG_EFFECT_SIZE="0.27816711270447697" ORDER="1" O_E="0.0" SE="0.43353395247856646" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.18795168795168793" WEIGHT="13.154478244174468"/>
<DICH_DATA CI_END="15.57186622953371" CI_START="0.7216000463493619" EFFECT_SIZE="3.352112676056338" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1923406642456564" LOG_CI_START="-0.14170344757078282" LOG_EFFECT_SIZE="0.5253186083374367" MODIFIED="2013-01-30 13:53:30 +0000" MODIFIED_BY="Katie Carmichael" ORDER="2" O_E="0.0" SE="0.7836241149058317" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="0.6140667534619482" WEIGHT="3.741089656919674"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5818066605853671" CI_END="2.2541101129393013" CI_START="1.195249702605411" DF="3" EFFECT_SIZE="1.641409285379655" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="45" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.3529751274482734" LOG_CI_START="0.0774586443093915" LOG_EFFECT_SIZE="0.21521688587883248" MODIFIED="2013-10-17 11:18:29 +0100" MODIFIED_BY="Katie Carmichael" NO="2" P_CHI2="0.6635220834499141" P_Z="0.0021985487101824843" STUDIES="5" TAU2="0.0" TOTAL_1="494" TOTAL_2="398" WEIGHT="100.0" Z="3.0620116835242097">
<NAME>300 to 500 mg zonisamide</NAME>
<DICH_DATA CI_END="2.528933103114955" CI_START="1.0754651980175254" EFFECT_SIZE="1.6491754122938531" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="23" LOG_CI_END="0.4029373412731152" LOG_CI_START="0.03159636121023692" LOG_EFFECT_SIZE="0.21726685124167608" MODIFIED="2013-01-10 18:50:22 +0000" MODIFIED_BY="Katie Carmichael" ORDER="4" O_E="0.0" SE="0.2181275298564316" STUDY_ID="STD-Brodie-2005" TOTAL_1="174" TOTAL_2="120" VAR="0.047579619281268457" WEIGHT="52.79628043238384"/>
<DICH_DATA CI_END="2.3698070205380057" CI_START="0.6853774675902221" EFFECT_SIZE="1.274445893089961" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="13" LOG_CI_END="0.3747129817367704" LOG_CI_START="-0.16407017749892353" LOG_EFFECT_SIZE="0.10532140211892348" ORDER="3" O_E="0.0" SE="0.316483894754698" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.10016205563910276" WEIGHT="29.309127812797275"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-04 14:22:54 +0000" MODIFIED_BY="Katie Carmichael" ORDER="136" O_E="0.0" SE="0.0" STUDY_ID="STD-Lu-2011" TOTAL_1="53" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.438046845544749" CI_START="0.8112269000703745" EFFECT_SIZE="1.8974358974358974" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6471918820902689" LOG_CI_START="-0.09085765668131479" LOG_EFFECT_SIZE="0.27816711270447697" ORDER="1" O_E="0.0" SE="0.43353395247856646" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.18795168795168793" WEIGHT="13.932293919040452"/>
<DICH_DATA CI_END="15.57186622953371" CI_START="0.7216000463493619" EFFECT_SIZE="3.352112676056338" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1923406642456564" LOG_CI_START="-0.14170344757078282" LOG_EFFECT_SIZE="0.5253186083374367" MODIFIED="2013-01-30 13:53:35 +0000" MODIFIED_BY="Katie Carmichael" ORDER="2" O_E="0.0" SE="0.7836241149058317" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="0.6140667534619482" WEIGHT="3.962297835778443"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="38.20370637979102" CI_END="2.2949871669998005" CI_START="1.4061208635545022" CI_STUDY="99" CI_TOTAL="99" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7963934249234659" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="142" I2="29.32622889625587" I2_Q="40.631632061299676" ID="CMP-001.07" LOG_CI_END="0.3607802614128203" LOG_CI_START="0.14802265220500405" LOG_EFFECT_SIZE="0.2544014568089122" METHOD="MH" MODIFIED="2013-11-04 09:41:08 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.07469882871023048" P_Q="0.12024262837425426" P_Z="7.273936991022985E-10" Q="10.10639202040249" RANDOM="NO" SCALE="105.86" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2596" TOTAL_2="2084" WEIGHT="700.0" Z="6.160012135442362">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Zonisamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Worse on placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Worse on zonisamide</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8810446610782436" CI_END="11.110088700245141" CI_START="1.2763722523827614" DF="2" EFFECT_SIZE="3.7657149305947413" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="6" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="1.0457175262561902" LOG_CI_START="0.10597735430552266" LOG_EFFECT_SIZE="0.5758474402808563" MODIFIED="2013-02-04 14:49:41 +0000" MODIFIED_BY="Katie Carmichael" NO="1" P_CHI2="0.390423915464557" P_Z="0.0015951208039922027" STUDIES="3" TAU2="0.0" TOTAL_1="267" TOTAL_2="227" WEIGHT="100.0" Z="3.1567974964188763">
<NAME>Ataxia</NAME>
<DICH_DATA CI_END="15.058865271640961" CI_START="0.2153582960695857" EFFECT_SIZE="1.8008474576271187" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1777922477722846" LOG_CI_START="-0.6668383936118748" LOG_EFFECT_SIZE="0.255476927080205" MODIFIED="2013-02-04 14:39:42 +0000" MODIFIED_BY="Katie Carmichael" ORDER="3" O_E="0.0" SE="0.8244760262411883" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.6797607178464606" WEIGHT="33.498269835693996"/>
<DICH_DATA CI_END="13.455350340936855" CI_START="0.8194365149783469" EFFECT_SIZE="3.3205128205128207" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="1.1288950101008763" LOG_CI_START="-0.08648468731933347" LOG_EFFECT_SIZE="0.5212051613907714" MODIFIED="2013-02-04 14:39:41 +0000" MODIFIED_BY="Katie Carmichael" ORDER="1" O_E="0.0" SE="0.5432260534018458" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.295094545094545" WEIGHT="59.144915764761244"/>
<DICH_DATA CI_END="674.4061192656536" CI_START="0.39355871068724296" EFFECT_SIZE="16.291666666666668" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.828921502232418" LOG_CI_START="-0.40499047086389683" LOG_EFFECT_SIZE="1.2119655156842608" MODIFIED="2013-02-04 14:49:41 +0000" MODIFIED_BY="Katie Carmichael" ORDER="2" O_E="0.0" SE="1.4454291460709696" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="2.089265416311452" WEIGHT="7.356814399544769"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.152759636215067" CI_END="2.4407284668689004" CI_START="0.8786272408062294" DF="4" EFFECT_SIZE="1.4644079071086173" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="35" I2="34.98852163091095" ID="CMP-001.07.02" LOG_CI_END="0.3875194664717176" LOG_CI_START="-0.05619533607134684" LOG_EFFECT_SIZE="0.1656620652001854" MODIFIED="2013-01-30 13:46:59 +0000" MODIFIED_BY="Katie Carmichael" NO="2" P_CHI2="0.18802701981743408" P_Z="0.05443171430387029" STUDIES="5" TAU2="0.0" TOTAL_1="551" TOTAL_2="398" WEIGHT="100.00000000000001" Z="1.9233850193115947">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="9.204642267037269" CI_START="0.3257535132705636" EFFECT_SIZE="1.7316017316017316" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.9640069145705402" LOG_CI_START="-0.48711089169890404" LOG_EFFECT_SIZE="0.2384480114358181" ORDER="4" O_E="0.0" SE="0.6485915476407287" STUDY_ID="STD-Brodie-2005" TOTAL_1="231" TOTAL_2="120" VAR="0.42067099567099564" WEIGHT="10.365021740674425"/>
<DICH_DATA CI_END="3.643654488490487" CI_START="0.5696349663688303" EFFECT_SIZE="1.4406779661016949" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.5615371880440302" LOG_CI_START="-0.24440335989973325" LOG_EFFECT_SIZE="0.1585669140721485" ORDER="3" O_E="0.0" SE="0.3602231500701484" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.12976071784646065" WEIGHT="30.516173021933145"/>
<DICH_DATA CI_END="2.4706591164872624" CI_START="0.04164216252217105" EFFECT_SIZE="0.32075471698113206" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.3928128287525094" LOG_CI_START="-1.3804667251975398" LOG_EFFECT_SIZE="-0.49382694822251516" MODIFIED="2013-01-22 14:04:48 +0000" MODIFIED_BY="Katie Carmichael" ORDER="131" O_E="0.0" SE="0.7925849474984431" STUDY_ID="STD-Lu-2011" TOTAL_1="53" TOTAL_2="51" VAR="0.6281908990011098" WEIGHT="16.052322630849677"/>
<DICH_DATA CI_END="3.1721433326578117" CI_START="0.6060967130508711" EFFECT_SIZE="1.3865877712031558" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.5013528025976464" LOG_CI_START="-0.21745807122467026" LOG_EFFECT_SIZE="0.14194736568648797" MODIFIED="2013-01-30 13:28:31 +0000" MODIFIED_BY="Katie Carmichael" ORDER="1" O_E="0.0" SE="0.3212796749506869" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.10322062953641901" WEIGHT="35.02180021844761"/>
<DICH_DATA CI_END="19.055224424329865" CI_START="0.7702062572386393" EFFECT_SIZE="3.8309859154929575" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.2800140680740273" LOG_CI_START="-0.11339295744378054" LOG_EFFECT_SIZE="0.5833105553151234" MODIFIED="2013-01-30 13:46:59 +0000" MODIFIED_BY="Katie Carmichael" ORDER="2" O_E="0.0" SE="0.6227971397425264" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="0.38787627727147195" WEIGHT="8.044682388095156"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5018740317303522" CI_END="2.4014771735472302" CI_START="0.613636695046885" DF="3" EFFECT_SIZE="1.213933489119588" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.3804784629509987" LOG_CI_START="-0.21208867777506088" LOG_EFFECT_SIZE="0.0841948925879689" MODIFIED="2013-01-30 13:47:11 +0000" MODIFIED_BY="Katie Carmichael" NO="3" P_CHI2="0.9184795563733585" P_Z="0.46418485206365157" STUDIES="4" TAU2="0.0" TOTAL_1="320" TOTAL_2="278" WEIGHT="100.0" Z="0.7319733297108386">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="3.302117873387293" CI_START="0.35356053550975375" EFFECT_SIZE="1.0805084745762712" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5187925719092024" LOG_CI_START="-0.4515362169815051" LOG_EFFECT_SIZE="0.033628177463848594" ORDER="3" O_E="0.0" SE="0.4336981106481719" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.18809405117979394" WEIGHT="40.196040587616295"/>
<DICH_DATA CI_END="188.16236719907974" CI_START="0.04435360341484104" EFFECT_SIZE="2.888888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.274532768123888" LOG_CI_START="-1.3530710910609018" LOG_EFFECT_SIZE="0.4607308385314931" MODIFIED="2013-01-22 14:04:54 +0000" MODIFIED_BY="Katie Carmichael" ORDER="132" O_E="0.0" SE="1.6213936532863877" STUDY_ID="STD-Lu-2011" TOTAL_1="53" TOTAL_2="51" VAR="2.6289173789173788" WEIGHT="2.2017358736481145"/>
<DICH_DATA CI_END="3.5430743156357116" CI_START="0.49790907709873256" EFFECT_SIZE="1.3282051282051281" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.5493802617128062" LOG_CI_START="-0.3028499562753386" LOG_EFFECT_SIZE="0.1232651527187338" MODIFIED="2013-01-30 13:28:55 +0000" MODIFIED_BY="Katie Carmichael" ORDER="1" O_E="0.0" SE="0.3809127788543528" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.14509454509454509" WEIGHT="44.35660868255997"/>
<DICH_DATA CI_END="7.493750922763168" CI_START="0.122405765450216" EFFECT_SIZE="0.9577464788732394" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8746992539209458" LOG_CI_START="-0.912198125946624" LOG_EFFECT_SIZE="-0.01874943601283899" MODIFIED="2013-01-30 13:47:11 +0000" MODIFIED_BY="Katie Carmichael" ORDER="2" O_E="0.0" SE="0.7986715703413212" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="0.637876277271472" WEIGHT="13.245614856175628"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.336953635547173" CI_END="2.617217218134094" CI_START="0.7564748104993941" DF="3" EFFECT_SIZE="1.4070745890405882" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="24" I2="59.11109502634513" ID="CMP-001.07.04" LOG_CI_END="0.4178397687698481" LOG_CI_START="-0.12120552876868652" LOG_EFFECT_SIZE="0.14831712000058078" MODIFIED="2013-01-30 13:47:31 +0000" MODIFIED_BY="Katie Carmichael" NO="4" P_CHI2="0.0618993386616975" P_Z="0.15634630203567423" STUDIES="4" TAU2="0.0" TOTAL_1="320" TOTAL_2="278" WEIGHT="100.0" Z="1.417467458337911">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="1.897976415139676" CI_START="0.22594235705859902" EFFECT_SIZE="0.6548536209553159" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.27829081144304685" LOG_CI_START="-0.6460023449431623" LOG_EFFECT_SIZE="-0.18385576675005771" ORDER="3" O_E="0.0" SE="0.41312202647105556" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.17066980875555154" WEIGHT="49.03771634653634"/>
<DICH_DATA CI_END="10.830835033888375" CI_START="0.021373058801413325" EFFECT_SIZE="0.4811320754716981" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="1.03466194107867" LOG_CI_START="-1.670133319412338" LOG_EFFECT_SIZE="-0.31773568916683387" MODIFIED="2013-01-22 14:05:01 +0000" MODIFIED_BY="Katie Carmichael" ORDER="133" O_E="0.0" SE="1.208935164652945" STUDY_ID="STD-Lu-2011" TOTAL_1="53" TOTAL_2="51" VAR="1.4615242323344433" WEIGHT="7.816711955854931"/>
<DICH_DATA CI_END="18.971566811404543" CI_START="0.7590860619301324" EFFECT_SIZE="3.7948717948717947" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.27810319959967" LOG_CI_START="-0.11970898286275374" LOG_EFFECT_SIZE="0.5791971083684582" ORDER="1" O_E="0.0" SE="0.6247660684869499" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.39033264033264026" WEIGHT="11.806572874732225"/>
<DICH_DATA CI_END="5.344903770348398" CI_START="0.6864694723843812" EFFECT_SIZE="1.9154929577464788" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.7279398905769959" LOG_CI_START="-0.16337877127471145" LOG_EFFECT_SIZE="0.2822805596511422" MODIFIED="2013-01-30 13:47:31 +0000" MODIFIED_BY="Katie Carmichael" ORDER="2" O_E="0.0" SE="0.39838374791751396" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="0.1587096106048053" WEIGHT="31.338998822876512"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.825675123933129" CI_END="3.1067203316373693" CI_START="1.0790610235581033" DF="4" EFFECT_SIZE="1.8309398736619915" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="30" I2="54.677688178743935" ID="CMP-001.07.05" LOG_CI_END="0.49230215962981816" LOG_CI_START="0.03304600579982824" LOG_EFFECT_SIZE="0.2626740827148232" MODIFIED="2013-01-30 13:47:48 +0000" MODIFIED_BY="Katie Carmichael" NO="5" P_CHI2="0.06560762520036267" P_Z="0.003213721862497559" STUDIES="5" TAU2="0.0" TOTAL_1="551" TOTAL_2="398" WEIGHT="100.0" Z="2.946519470222008">
<NAME>Somnolence</NAME>
<DICH_DATA CI_END="49.595874766796896" CI_START="0.19588242792351998" EFFECT_SIZE="3.116883116883117" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6954455547054577" LOG_CI_START="-0.7080045216272092" LOG_EFFECT_SIZE="0.4937205165391242" ORDER="4" O_E="0.0" SE="1.074245935065304" STUDY_ID="STD-Brodie-2005" TOTAL_1="231" TOTAL_2="120" VAR="1.1540043290043291" WEIGHT="4.064330371460073"/>
<DICH_DATA CI_END="3.1947103187460058" CI_START="0.46939687619048615" EFFECT_SIZE="1.2245762711864407" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.5044314845057681" LOG_CI_START="-0.3284598049328855" LOG_EFFECT_SIZE="0.0879858397864413" ORDER="3" O_E="0.0" SE="0.372269052243435" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.13858424725822532" WEIGHT="35.89798804195367"/>
<DICH_DATA CI_END="2.4706591164872624" CI_START="0.04164216252217105" EFFECT_SIZE="0.32075471698113206" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.3928128287525094" LOG_CI_START="-1.3804667251975398" LOG_EFFECT_SIZE="-0.49382694822251516" MODIFIED="2013-01-22 14:05:26 +0000" MODIFIED_BY="Katie Carmichael" ORDER="134" O_E="0.0" SE="0.7925849474984431" STUDY_ID="STD-Lu-2011" TOTAL_1="53" TOTAL_2="51" VAR="0.6281908990011098" WEIGHT="18.883301173894044"/>
<DICH_DATA CI_END="6.60972203948928" CI_START="1.225557091142406" EFFECT_SIZE="2.8461538461538463" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="10" LOG_CI_END="0.8201831963609467" LOG_CI_START="0.08833354715936988" LOG_EFFECT_SIZE="0.45425837176015826" MODIFIED="2013-01-30 13:29:06 +0000" MODIFIED_BY="Katie Carmichael" ORDER="1" O_E="0.0" SE="0.3271074853917394" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.106999306999307" WEIGHT="31.69094238717074"/>
<DICH_DATA CI_END="16.43023326275064" CI_START="0.6203187225545774" EFFECT_SIZE="3.192488262910798" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.2156437292297246" LOG_CI_START="-0.2073851106947276" LOG_EFFECT_SIZE="0.5041293092674985" MODIFIED="2013-01-30 13:47:48 +0000" MODIFIED_BY="Katie Carmichael" ORDER="2" O_E="0.0" SE="0.6360369045410327" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="0.40454294393813867" WEIGHT="9.463438025521489"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0496131432252187" CI_END="5.273611053837448" CI_START="1.046606642435667" DF="3" EFFECT_SIZE="2.349339557954199" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="12" I2="1.626866782609308" ID="CMP-001.07.06" LOG_CI_END="0.7221080959919056" LOG_CI_START="0.0197834867231594" LOG_EFFECT_SIZE="0.3709457913575325" MODIFIED="2013-01-30 13:49:50 +0000" MODIFIED_BY="Katie Carmichael" NO="6" P_CHI2="0.38403911201450014" P_Z="0.006509574675701245" STUDIES="4" TAU2="0.0" TOTAL_1="320" TOTAL_2="278" WEIGHT="100.0" Z="2.720944209549254">
<NAME>Agitation/irritability</NAME>
<DICH_DATA CI_END="4.355746433051378" CI_START="0.2334894803031232" EFFECT_SIZE="1.0084745762711864" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6390625896485034" LOG_CI_START="-0.6317326814756928" LOG_EFFECT_SIZE="0.003664954086405364" ORDER="3" O_E="0.0" SE="0.5679945956640815" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.3226178607036035" WEIGHT="43.06745054203195"/>
<DICH_DATA CI_END="188.16236719907974" CI_START="0.04435360341484104" EFFECT_SIZE="2.888888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.274532768123888" LOG_CI_START="-1.3530710910609018" LOG_EFFECT_SIZE="0.4607308385314931" MODIFIED="2013-01-22 14:06:34 +0000" MODIFIED_BY="Katie Carmichael" ORDER="135" O_E="0.0" SE="1.6213936532863877" STUDY_ID="STD-Lu-2011" TOTAL_1="53" TOTAL_2="51" VAR="2.6289173789173788" WEIGHT="3.7744275091281922"/>
<DICH_DATA CI_END="11.722641041255084" CI_START="0.9950703113704674" EFFECT_SIZE="3.4153846153846152" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" LOG_CI_END="1.069025466667472" LOG_CI_START="-0.0021462310519057225" LOG_EFFECT_SIZE="0.533439617807783" MODIFIED="2013-01-30 13:29:55 +0000" MODIFIED_BY="Katie Carmichael" ORDER="1" O_E="0.0" SE="0.47877085251874846" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.2292215292215292" WEIGHT="38.02018353493165"/>
<DICH_DATA CI_END="25.230983790347466" CI_START="0.44535161555120806" EFFECT_SIZE="3.352112676056338" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.4019341845797832" LOG_CI_START="-0.35129696790490983" LOG_EFFECT_SIZE="0.5253186083374367" MODIFIED="2013-01-30 13:49:50 +0000" MODIFIED_BY="Katie Carmichael" ORDER="2" O_E="0.0" SE="0.7836241149058317" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="0.6140667534619482" WEIGHT="15.13793841390822"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3491639810844696" CI_END="5.693275022146275" CI_START="1.291952096471483" DF="2" EFFECT_SIZE="2.712091185902607" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="14" I2="14.86332941829294" ID="CMP-001.07.07" LOG_CI_END="0.7553621635613462" LOG_CI_START="0.11124641100907466" LOG_EFFECT_SIZE="0.4333042872852105" MODIFIED="2013-01-30 13:50:15 +0000" MODIFIED_BY="Katie Carmichael" NO="7" P_CHI2="0.30894814625342093" P_Z="5.290857589714485E-4" STUDIES="3" TAU2="0.0" TOTAL_1="267" TOTAL_2="227" WEIGHT="100.0" Z="3.465581694346283">
<NAME>Anorexia</NAME>
<DICH_DATA CI_END="5.240770189125513" CI_START="0.5839564819505074" EFFECT_SIZE="1.7493946731234866" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.719395116050064" LOG_CI_START="-0.23361951650569526" LOG_EFFECT_SIZE="0.24288779977218444" ORDER="3" O_E="0.0" SE="0.4259593761327108" STUDY_ID="STD-Faught-2001" TOTAL_1="118" TOTAL_2="85" VAR="0.1814413901153682" WEIGHT="53.12864138704081"/>
<DICH_DATA CI_END="9.314181763011405" CI_START="0.9690233149972028" EFFECT_SIZE="3.0042735042735043" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.9691447087848842" LOG_CI_START="-0.01366577356552198" LOG_EFFECT_SIZE="0.4777394676096811" MODIFIED="2013-01-30 13:31:52 +0000" MODIFIED_BY="Katie Carmichael" ORDER="1" O_E="0.0" SE="0.4392769277801974" STUDY_ID="STD-Sackellares-2004" TOTAL_1="78" TOTAL_2="74" VAR="0.19296421928000873" WEIGHT="40.201935822085076"/>
<DICH_DATA CI_END="125.68857990834823" CI_START="0.5911399730627891" EFFECT_SIZE="8.619718309859154" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="2.099295819387634" LOG_CI_START="-0.22830967253466206" LOG_EFFECT_SIZE="0.9354930734264859" MODIFIED="2013-01-30 13:50:15 +0000" MODIFIED_BY="Katie Carmichael" ORDER="2" O_E="0.0" SE="1.0403464431216731" STUDY_ID="STD-Schmidt-1993" TOTAL_1="71" TOTAL_2="68" VAR="1.0823207217159165" WEIGHT="6.669422790874103"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-10-29 15:01:45 +0000" MODIFIED_BY="Katie Carmichael">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-10-17 11:21:57 +0100" MODIFIED_BY="Katie Carmichael" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAALPCAYAAABIekZOAABF4ElEQVR42u2dfaQW2/v/D0mSJJJs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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-10-29 15:01:45 +0000" MODIFIED_BY="Katie Carmichael" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUsAAAHrCAIAAADJySgnAAAVq0lEQVR42u3dv44dVRLH8ZGQEIED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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-10-17 11:23:24 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-10-17 11:22:51 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-10-17 11:22:51 +0100" MODIFIED_BY="[Empty name]">Cochrane Epilepsy Group Specialised Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-18 22:44:12 +0100" MODIFIED_BY="[Empty name]">
<P>#1 Zonisamide or Zonegran or Excegran</P>
<P>#2 monotherap* not (adjunct* or "add-on" or "add on")</P>
<P>#3 #1 NOT #2</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-10-17 11:23:24 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-06-18 13:47:10 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-17 11:23:24 +0100" MODIFIED_BY="[Empty name]">
<P>#1 (zonisamide or zonegran or excegran):ti,ab,kw (Word variations have been searched)</P>
<P>#2 (monotherap* not (adjunct* or "add-on" or "add on")):ti,ab,kw  (Word variations have been searched)</P>
<P>#3 #1 not #2</P>
<P>#4 (epilep* or seizure* or convuls*):ti,ab,kw  (Word variations have been searched)</P>
<P>#5 MeSH descriptor: [Epilepsy] explode all trees</P>
<P>#6 MeSH descriptor: [Seizures] explode all trees</P>
<P>#7 (#4 or #5 or #6) in Trials</P>
<P>#8 #3 and #7</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-06-18 22:45:32 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-06-18 13:46:46 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-18 22:45:32 +0100" MODIFIED_BY="[Empty name]">
<P>The following search strategy was used in updating the searches from February 2013 onwards. It is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials published in <LINK REF="REF-Lefebvre-2009" TYPE="REFERENCE">Lefebvre 2009</LINK>.</P>
<P>1. (randomized controlled trial or controlled clinical trial).pt. or (randomized or placebo or randomly).ab.</P>
<P>2. clinical trials as topic.sh.</P>
<P>3. trial.ti.</P>
<P>4. 1 or 2 or 3</P>
<P>5. exp animals/ not humans.sh.</P>
<P>6. 4 not 5</P>
<P>7. exp Epilepsy/</P>
<P>8. exp Seizures/</P>
<P>9. (epilep$ or seizure$ or convuls$).tw.</P>
<P>10. 7 or 8 or 9</P>
<P>11. exp Pre-Eclampsia/ or exp Eclampsia/</P>
<P>12. 10 not 11</P>
<P>13. (Zonisamide or Zonegran or Excegran).tw.</P>
<P>14. (monotherap* not (adjunct* or "add-on" or "add on")).tw.</P>
<P>15. 13 not 14</P>
<P>16. 6 and 12 and 15</P>
<P>---------------------</P>
<P>The search strategy below is the original MEDLINE strategy that was used for earlier versions of this review:</P>
<P>1. randomized controlled trial.pt.</P>
<P>2. controlled clinical trial.pt.</P>
<P>3. exp Randomized Controlled Trials/</P>
<P>4. exp Random Allocation/</P>
<P>5. exp Double-Blind Method/</P>
<P>6. exp Single-Blind Method/</P>
<P>7. clinical trial.pt.</P>
<P>8. Clinical Trial/</P>
<P>9. (clin$ adj trial$).ab,ti.</P>
<P>10. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ab,ti.</P>
<P>11. exp PLACEBOS/</P>
<P>12. placebo$.ab,ti.</P>
<P>13. random$.ab,ti.</P>
<P>14. exp Research Design/</P>
<P>15. or/1-14</P>
<P>16. (animals not humans).sh.</P>
<P>17. 15 not 16</P>
<P>18. (zonisamide or zonegran).tw.</P>
<P>19. exp EPILEPSY/</P>
<P>20. exp SEIZURES/</P>
<P>21. (epilep$ or seizure$ or convulsion$).tw.</P>
<P>22. 19 or 20 or 21</P>
<P>23. 17 and 18 and 22</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-06-18 22:45:55 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-06-18 22:45:47 +0100" MODIFIED_BY="[Empty name]">SCOPUS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-18 22:45:55 +0100" MODIFIED_BY="[Empty name]">
<P>((TITLE-ABS-KEY(Zonisamide or Zonegran or Excegran)) and not (TITLE-ABS-KEY(monotherap* AND NOT (adjunct* or "add-on" or "add on")))) and (((TITLE-ABS-KEY(epilep* OR "infantile spasm" OR seizure OR convuls* OR (syndrome W/2 (aicardi OR angelman OR doose OR dravet OR janz OR jeavons OR "landau kleffner" OR "lennox gastaut" OR ohtahara OR panayiotopoulos OR rasmussen OR rett OR "sturge weber" OR tassinari OR "unverricht lundborg" OR west)) OR "ring chromosome 20" OR "R20" OR "myoclonic encephalopathy" OR "pyridoxine dependency") AND NOT (TITLE(*eclampsia) OR INDEXTERMS(*eclampsia))) OR (TITLE-ABS-KEY(lafora* W/4 (disease OR epilep*)) AND NOT (TITLE(dog OR canine) OR INDEXTERMS(dog OR canine)))) and (TITLE-ABS-KEY(refractor* OR resist* OR nonrespons* OR non-respons* OR intractable))) and (TITLE((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR "parallel group" OR crossover or cross-over) PRE/2 (trial OR method OR procedure OR study)) OR ABS((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR "parallel group" OR crossover or cross-over) PRE/2 (trial OR method OR procedure OR study))) AND ( EXCLUDE(EXACTKEYWORD,"Animal experiment" ) OR EXCLUDE(EXACTKEYWORD,"Animal model" ) )</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in narrative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;206 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;206 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;292 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;199 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 full-text article excluded due to no control group; 1 study in awaiting classification: no full report available&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>